<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical use of neuromuscular blocking agents in anesthesia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical use of neuromuscular blocking agents in anesthesia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical use of neuromuscular blocking agents in anesthesia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johnathan Ross Renew, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3496590383"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuromuscular blocking agents (NMBAs) are usually administered during anesthesia to facilitate endotracheal intubation and/or to improve surgical conditions. NMBAs may decrease the incidence of hoarseness and vocal cord injuries during intubation, and can facilitate mechanical ventilation in patients with poor lung compliance [<a href="#rid1">1-5</a>].</p><p>This topic will discuss the clinical use and pharmacology of the commonly used NMBAs and reversal of neuromuscular block. Monitoring neuromuscular blockade is discussed separately. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade"</a>.)</p><p class="headingAnchor" id="H679390746"><span class="h1">SELECTION OF NEUROMUSCULAR BLOCKING AGENTS</span><span class="headingEndMark"> — </span>The selection of the appropriate NMBA depends on the clinical application and patient factors. For patients without contraindications to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> (eg, hyperkalemia, burns, stroke, susceptibility to malignant hyperthermia), options include the following (see <a class="local">'Adverse effects of succinylcholine'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>For endotracheal intubation for short procedures (&lt;30 minutes), or if neuromonitoring will be used soon after intubation, a short duration of neuromuscular block is required. Options for endotracheal intubation include <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, intubation without an NMBA (eg, high dose <a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">remifentanil</a> intubation, although this technique is associated with more trauma), or <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> if <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> is available for rapid reversal of block. (See <a class="local">'Sugammadex'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For endotracheal intubation for longer procedures (≥30 minutes), <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> or any of the short or intermediate acting nondepolarizing NMBAs can be used for endotracheal intubation (<a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, mivacurium, <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a>, or <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>). The choice among these agents depends on availability, cost, and patient factors that affect metabolism. <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">Pancuronium</a> (no longer available in North America or Europe) is a rarely used, long acting alternative and should be avoided. (See <a class="local">'Nondepolarizing neuromuscular blocking agents'</a> below.)</p><p></p><p class="bulletIndent1">Intraoperative relaxation can be maintained as necessary with additional doses of nondepolarizing NMBA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> provides the most reliable and fastest intubating conditions, and is therefore the preferred NMBA for rapid sequence induction and intubation (RSII). Alternatives to succinylcholine for RSII include high dose <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> (1.2 mg/kg which is a 4 X ED95 dose), or avoidance of NMBAs with a high dose <a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">remifentanil</a> intubation. (See  <a class="medical medical_review" href="/d/html/94214.html" rel="external">"Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Neuromuscular blocking agents (NMBAs)'</a>.)</p><p></p><p class="headingAnchor" id="H2359769701"><span class="h1">FACTORS THAT AFFECT THE RESPONSE TO NEUROMUSCULAR BLOCKING AGENTS</span></p><p class="headingAnchor" id="H1330254603"><span class="h2">Patient factors</span><span class="headingEndMark"> — </span>A number of patient factors can affect the response to NMBAs or require modification of the dose or interval of administration.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular disease </strong>–<strong> </strong>NMBAs should be avoided or doses should be modified in patients with some neuromuscular diseases  (<a class="graphic graphic_table graphicRef114209" href="/d/graphic/114209.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> may cause life threatening hyperkalemia, and should be avoided, in conditions associated with denervation and associated upregulation of nicotinic acetylcholine receptors (nAChRs). (See <a class="local">'Adverse effects of succinylcholine'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensitivity to nondepolarizing NMBAs may be increased or variable in patients with neuromuscular diseases, and administration should be titrated, using careful monitoring.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with myasthenia gravis are resistant to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, but extremely sensitive to nondepolarizing NMBAs. The use of NMBAs in patients with myasthenia gravis is discussed separately. (See  <a class="medical medical_review" href="/d/html/94256.html" rel="external">"Anesthesia for the patient with myasthenia gravis", section on 'Neuromuscular blocking agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> is contraindicated in patients with neuromuscular diseases associated with susceptibility to malignant hyperthermia  (<a class="graphic graphic_table graphicRef65645" href="/d/graphic/65645.html" rel="external">table 2</a>). (See <a class="local">'Adverse effects of succinylcholine'</a> below and  <a class="medical medical_review" href="/d/html/403.html" rel="external">"Susceptibility to malignant hyperthermia: Evaluation and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burns </strong>–<strong> </strong>Burn injury upregulates extrajunctional nAChRs beginning within 24 hours of injury. As a result, administration of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> after 48 hours, and for up to a year after a major burn, can cause severe hyperkalemia and life threatening arrhythmias, and should be avoided. Upregulation of nAChRs also causes resistance to nondepolarizing NMBAs and reduces duration of action. (See  <a class="medical medical_review" href="/d/html/94580.html" rel="external">"Anesthesia for patients with acute burn injuries", section on 'Use of succinylcholine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extremes of age </strong>– In older adult patients, the effects of steroidal NMBAs are prolonged due to decreased volume of distribution, changes in circulatory physiology, decreased regional renal and hepatic blood flow, and anatomic changes at the neuromuscular junction (NMJ). As such, smaller doses and less frequent dosing intervals may be warranted. The use of objective monitoring is particularly useful in this patient population  (<a class="graphic graphic_table graphicRef114210" href="/d/graphic/114210.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef114207" href="/d/graphic/114207.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">Administration of NMBAs in infants and children is discussed separately. (See  <a class="medical medical_review" href="/d/html/106984.html" rel="external">"General anesthesia in neonates and children: Agents and techniques", section on 'Neuromuscular blocking agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity </strong>–<strong> </strong>The dose of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> should be based on total body weight for optimal intubating conditions [<a href="#rid6">6</a>]. Studies of the effects of obesity on the pharmacodynamics of various nondepolarizing NMBAs are conflicting, and the optimal method for calculating doses in very obese patients is unclear [<a href="#rid7">7,8</a>]. We calculate doses for nondepolarizing NMBAs based on ideal body weight plus 10 percent, and use objective neuromuscular monitoring to minimize the risk of prolonged paralysis [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic and renal disease </strong>–<strong> </strong>Benzylisoquinolinium NMBAs are preferred for patients with hepatic or renal dysfunction, since clearance of these drugs is independent of organ function. The duration of action of the steroidal NMBAs may be prolonged in these patients because of decreased clearance  (<a class="graphic graphic_table graphicRef114271" href="/d/graphic/114271.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> may be used for patients with renal disease, as long as serum potassium is normal. In these patients, the transient rise in potassium associated with succinylcholine is similar to patients without renal disease [<a href="#rid10">10</a>]. (See <a class="local">'Adverse effects of succinylcholine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiologic derangements</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypothermia </strong>–<strong> </strong>Hypothermia causes a prolonged response to nondepolarizing NMBAs as lower temperatures can affect excretion, volume of distribution, interactions with postjunctional nAChRs, and the pH at the NMJ [<a href="#rid11">11,12</a>]. This response is proportional to the degree of hypothermia but becomes more pronounced when muscle temperature is lower than 35.2°C [<a href="#rid13">13</a>]. It is important to note that neuromuscular monitoring is still reliable in this setting and can help guide neuromuscular blockade management in the hypothermic patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electrolyte disturbances</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypermagnesemia causes muscle relaxation, potentiates the effects of NMBAs, and can prolong the duration of action of <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>, and <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>. Hypermagnesemia is usually iatrogenic. As an example, magnesium is routinely administered in the intrapartum and postpartum period for patients with preeclampsia to prevent seizures. If these patients require general anesthesia, nondepolarizing NMBAs are rarely necessary and should be avoided. Since magnesium does not potentiate the effects of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, usual rapid sequence induction and intubation doses (succinylcholine 1 to 1.5 mg/kg IV) should be administered. (See  <a class="medical medical_review" href="/d/html/94369.html" rel="external">"Anesthesia for the patient with preeclampsia", section on 'Intraoperative magnesium'</a>.)</p><p></p><p class="bulletIndent3">The use of magnesium to reduce dose of NMBA can result in unpredictable neuromuscular blockade and increase the incidence of residual paralysis, which can increase postoperative pulmonary complications. In a meta-analysis of 21 randomized trials, the median dose reduction of NMBA after administration of magnesium was approximately 25 percent (interquartile range 14.7 to 31 percent), without an increase in complications [<a href="#rid14">14</a>]. Here was wide variation in the dose of magnesium and the overall quality of evidence was moderate, with high statistical heterogeneity.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypercalcemia causes a reduced response to the administration of nondepolarizing NMBAs as calcium triggers the release of acetylcholine into the NMJ and enhances the excitation-contraction coupling of the myocytes [<a href="#rid15">15</a>]. Thus, hypercalcemic patients may require larger doses of nondepolarizing NMBA to achieve the desired level of neuromuscular blockade.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypocalcemia should be confirmed by measuring ionized calcium, and excluding falsely low levels of calcium due to low plasma albumin levels. Plasma calcium can have antagonistic actions at the neuromuscular junction; at the presynaptic membrane, it can decrease the amplitude of depolarization, thus antagonizing nondepolarizing block [<a href="#rid16">16</a>]. At the postsynaptic membrane, calcium decreases the degree of depolarization produced by acetylcholine, thus potentiating nondepolarizing block [<a href="#rid17">17</a>]. For these reasons, the overall effect of calcium on neuromuscular transmission is unpredictable [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypokalemia may prolong the duration of nondepolarizing agents, but has no effect on the duration of depolarizing block [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acidosis </strong>–<strong> </strong>Acidosis, whether metabolic or respiratory in origin, can prolong the effects of NMBAs, by increasing NMBA affinity for postjunctional nAChRs. Acidosis also causes a relative hypocalcemia, which can prolong neuromuscular block [<a href="#rid16">16,19</a>]. Conversely, alkalosis can shorten the duration of neuromuscular blockade produced by nondepolarizing muscle relaxants, but will not affect the duration of action of depolarizing muscle relaxants [<a href="#rid18">18</a>]. These perturbations can occur once pH becomes lower than 7.3 or greater than 7.51 [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H2313054767"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>A number of drugs can either enhance or inhibit the response to NMBAs, and may require modification of the dose or interval of administration, guided by monitoring.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combinations of NMBAs </strong>–<strong> </strong>In some clinical circumstances,<strong> </strong><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> may be administered before or after a nondepolarizing NMBA, or two different nondepolarizing NMBAs may be administered in sequence. Combinations of NMBAs can affect the resulting degree of neuromuscular block, and subsequent management should be guided by the use of a neuromuscular function monitor.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior administration of any nondepolarizing neuromuscular blocking drug has a substantial antagonistic effect on the subsequent depolarizing block induced by <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. As an example, if a defasciculating dose of a nondepolarizing NMBA is administered prior to succinylcholine, the dose of succinylcholine must be increased [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In contrast, the effect of prior administration of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> on subsequent administration of a nondepolarizing neuromuscular block depends on the drug used. Studies have reported that administration of succinylcholine prior to a nondepolarizing NMBA does not affect the potency of mivacurium [<a href="#rid21">21</a>] or <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> [<a href="#rid22">22</a>], but speeds the onset, increases the potency, and prolongs the duration of action of <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> and <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a> [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combining two nondepolarizing NMBAs of the same structural class, such as <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> and <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, produces an additive interaction [<a href="#rid24">24</a>]. Combining two nondepolarizing NMBAs from different structural classes, such as rocuronium and <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>, results in a synergistic response [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled anesthetics </strong>–<strong> </strong>Inhaled anesthetics inhibit nAChRs and potentiate neuromuscular blockade with nondepolarizing NMBAs. This potentiation depends on the type of volatile anesthetic (<a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> &gt; <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> &gt; <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> &gt; <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a>), the concentration, and the duration of exposure [<a href="#rid26">26-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – Tetracyclines, aminoglycosides, polymyxins, and <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> potentiate neuromuscular blockade through inhibition of acetylcholine (ACh) release or desensitization of postjunctional nAChRs to ACh [<a href="#rid29">29</a>]. In practice, this interaction is most relevant during maintenance of anesthesia. Antibiotics typically are given after a dose of NMBA has already been administered for induction of anesthesia. Thus the interaction between such antibiotics and nondepolarizing NMBAs must be considered when redosing NMBAs. Appropriate (objective) monitoring is particularly helpful in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiseizure drugs </strong>– Patients receiving chronic treatment are relatively resistant to nondepolarizing NMBAs due to accelerated clearance of these drugs [<a href="#rid30">30,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong><strong> </strong>–<strong> </strong>Patients who take <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> can have a prolonged response to both depolarizing and nondepolarizing NMBAs [<a href="#rid32">32</a>]. Lithium structurally resembles other cations, such as sodium, potassium, magnesium, and calcium. This resemblance to such cations activates potassium channels, inhibiting neuromuscular transmission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidepressants </strong>–<strong> </strong>In laboratory studies, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> and <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> inhibit butyrylcholinesterase [<a href="#rid33">33</a>], and prolonged paralysis after administration of mivacurium has been reported in a patient who was chronically taking sertraline [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local anesthetics </strong>– Local anesthetics (LAs) may enhance the effects of both depolarizing and nondepolarizing NMBAs through pre- and post-synaptic interactions at the neuromuscular junction (NMJ) [<a href="#rid35">35,36</a>]. Administration of LAs for regional anesthesia may result in blood levels high enough to potentiate NMBA-induced neuromuscular block. Epidurally administered levobupivacaine [<a href="#rid37">37</a>] and <a class="drug drug_general" data-topicid="9610" href="/d/drug information/9610.html" rel="external">mepivacaine</a> [<a href="#rid38">38</a>] potentiate amino-steroidal NMBAs and delay recovery from neuromuscular blockade.</p><p></p><p class="bulletIndent1">Data on the effects of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> on neuromuscular block are conflicting. Whereas one study reported that epidural lidocaine potentiated vecuronium-induced neuromuscular block [<a href="#rid39">39</a>], several studies have reported no effect of intravenous (IV) lidocaine on the onset, duration, or recovery from rocuronium-induced neuromuscular block [<a href="#rid40">40-42</a>].</p><p></p><p class="headingAnchor" id="H115343747"><span class="h1">CLINICAL USE OF NEUROMUSCULAR BLOCKING AGENTS</span></p><p class="headingAnchor" id="H2476711246"><span class="h2">Endotracheal intubation</span><span class="headingEndMark"> — </span>The most common indication for the use of NMBAs in anesthesia is to facilitate endotracheal intubation. The goal of muscle paralysis for endotracheal intubation is to achieve ideal intubation conditions, which are dependent on the depth of anesthesia, airway anatomy, and the experience of the anesthesiologist, in addition to the depth of neuromuscular block  (<a class="graphic graphic_table graphicRef114082" href="/d/graphic/114082.html" rel="external">table 6</a>). More intense block is associated with better intubation conditions; a dose of 2 X ED95 for a given NMBA should be sufficient for routine intubation [<a href="#rid43">43,44</a>].</p><p>The use of NMBAs may reduce the incidence of postintubation hoarseness and airway injury [<a href="#rid5">5,45</a>]. A 2018 meta-analysis of randomized controlled trials that compared endotracheal intubation with NMBAs and without NMBAs reported increased risks of difficult intubation and an increased risk of upper airway discomfort and injury if NMBAs were avoided for intubation, but the overall quality of the evidence was moderate to low [<a href="#rid46">46</a>].</p><p><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> is commonly used for endotracheal intubation because of its reliable and rapid onset of neuromuscular blockade. Skeletal muscle relaxation can be assumed immediately after resolution of the fasciculations that occur with succinylcholine (see <a class="local">'Adverse effects of succinylcholine'</a> below). After administration of succinylcholine, a nondepolarizing NMBA should not be administered until return of neuromuscular function has been documented, as confirmation of normal pseudocholinesterase activity. (See <a class="local">'Butyrylcholinesterase (pseudocholinesterase) deficiency'</a> below.)</p><p>Nondepolarizing NMBAs do not cause fasciculations. Therefore, we suggest the use of an objective neuromuscular function monitor to determine when optimal neuromuscular blockade is achieved after administration of nondepolarizing NMBAs for endotracheal intubation. Central muscle groups (eg, the diaphragm and laryngeal adductors) are blocked faster than peripheral muscle groups (eg, adductor pollicis) after the administration of NMBA [<a href="#rid47">47</a>]. Therefore, if optimal neuromuscular blockade (defined as total suppression of evoked responses to train-of-four [TOF] stimulation) is confirmed by monitoring adductor pollicis stimulation, pharyngeal muscles are usually blocked as well, and optimal intubating conditions are achieved.</p><p>The onset time of nondepolarizing NMBAs can be shortened by increasing the dose. As an example, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> can be used for rapid sequence induction and intubation within 60 seconds by administration of twice the usual intubation dose (or four times the ED<sub>95</sub>). (See <a class="local">'Rocuronium'</a> below and  <a class="medical medical_review" href="/d/html/94214.html" rel="external">"Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Nondepolarizing NMBAs'</a>.)</p><p>Rapid onset of paralysis can also be achieved by administration of a priming dose (10 percent of the intubating dose) several minutes prior to the intubating dose [<a href="#rid48">48</a>]. Since the priming dose of NMBA may cause signs of paralysis, including diplopia, blurry vision, difficulty swallowing, and risk of aspiration, we do not routinely administer a priming dose of NMBA [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H1994682241"><span class="h2">Facilitation of surgery</span><span class="headingEndMark"> — </span>Nondepolarizing NMBAs may be used to provide muscle relaxation that improves surgical conditions. However, many operations can be performed without the need to use any NMBAs, and administration of NMBAs should be individualized [<a href="#rid50">50,51</a>]. Neuromuscular blockade may improve surgical conditions during laparoscopic, robotic, abdominal, and thoracic procedures, by reducing patient movement, muscle tone, and breathing or coughing against the ventilator [<a href="#rid2">2,52-55</a>]. NMBAs also allow lower insufflation pressures during laparoscopy, but the relationship between insufflation pressure and surgical exposure is unclear. The benefits of deep versus moderate muscle relaxation during laparoscopy are also unclear [<a href="#rid56">56-59</a>]. Many of the theoretical benefits of neuromuscular blockade can be achieved by making sure that patients are adequately anesthetized at all times during surgery  (<a class="graphic graphic_table graphicRef114082" href="/d/graphic/114082.html" rel="external">table 6</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate neuromuscular block </strong>–<strong> </strong>When neuromuscular blockade is indicated, for most surgical procedures we aim for moderate levels of blockade (ie, one to three twitches using an objective peripheral nerve stimulator  (<a class="graphic graphic_figure graphicRef114139" href="/d/graphic/114139.html" rel="external">figure 1</a>)). (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Train-of-four'</a>.)</p><p></p><p class="bulletIndent1">Once neuromuscular block begins to recover from the deep level of paralysis required for endotracheal intubation, a moderate level of block may be maintained with interval dosing or an infusion of nondepolarizing NMBA, guided by monitoring. When guided by objective monitoring, administration of NMBAs by infusion may reduce the total dose required for surgical relaxation [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent1">At the conclusion of abdominal surgery, a moderate level of relaxation of abdominal muscles is often sufficient to facilitate closure of the wound. A deep level of block should be avoided at this stage of the operation to allow rapid and complete reversal of the NMBA. If necessary, the anesthetic can be deepened temporarily (ie, with inhalation agent or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>) to facilitate closure without administration of NMBA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deep neuromuscular blockade </strong>–<strong> </strong>Deep levels of neuromuscular blockade (zero twitches and post tetanic count &gt;1) may be warranted in specific settings, in addition to ensuring adequate depth of anesthesia. As an example, complete paralysis may be indicated during delicate dissection under the microscope during craniotomy, when any unexpected movement must be avoided. (See  <a class="medical medical_review" href="/d/html/94284.html" rel="external">"Anesthesia for intracranial neurovascular procedures in adults", section on 'Patient immobility'</a>.)</p><p></p><p class="headingAnchor" id="H1726332908"><span class="h1">AVOIDANCE OF RESIDUAL NEUROMUSCULAR BLOCKADE</span><span class="headingEndMark"> — </span>One primary goal for anesthetic management is to ensure complete recovery of neuromuscular function at the end of anesthesia (ie, train-of-four ratio [TOFR] ≥0.9).</p><p class="headingAnchor" id="H1293097603"><span class="h2">Consequences of residual block</span><span class="headingEndMark"> — </span>Residual neuromuscular block after administration of NMBAs is an important risk factor for anesthesia-related morbidity and mortality. Even minor degrees of residual block are associated with weakness of upper airway muscles, airway obstruction, increased risk of aspiration, and unpleasant muscle weakness. Incomplete postoperative neuromuscular recovery can also cause prolonged recovery room stay, hypoxemia and airway obstruction, awareness during emergence from anesthesia, and increased postoperative pulmonary complications [<a href="#rid61">61-63</a>].</p><p>A prospective international observational study including approximately 22,000 patients who underwent general anesthesia for noncardiac surgery at 1 of over 200 hospitals reported that the use of NMBAs was independently associated with an increase in postoperative pulmonary complications within 28 days of surgery [<a href="#rid64">64</a>]. In contrast with other literature, in this study neither the use of neuromuscular monitoring nor administration of reversal agents was associated with a reduction in postoperative pulmonary complications. The utility of this study has been questioned and a number of concerns have been raised, including poorly described reversal administration and the utilization of uncalibrated acceleromyographic data to confirm recovery [<a href="#rid65">65-68</a>]. A post hoc analysis of the study found that raising the threshold for extubation from a TOFR ≥0.9 to TOFR ≥0.95 was associated with a lower incidence of postoperative pulmonary complications [<a href="#rid69">69</a>]. These findings reinforce the need to calibrate accelerometers prior to administration of NMBAs, and support the need to increase the reversal threshold for extubation if calibration is not performed. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Acceleromyography (AMG)'</a>.)</p><p class="headingAnchor" id="H4013702752"><span class="h2">Incidence of residual block</span><span class="headingEndMark"> — </span>Multiple studies have reported that residual neuromuscular block is a common problem [<a href="#rid70">70-72</a>]. In a meta-analysis of 24 randomized and observational studies including 3375 patients anesthetized between 1979 and 2005, residual block (TOFR &lt;0.9) occurred in 41 percent of patients who received intermediate acting NMBAs [<a href="#rid73">73</a>]. A 2020 meta-analysis of 53 observational and randomized trials found that for patients who received intermediate-acting NMBAs (ie, <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a>, <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>, mivacurium, <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, or <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>), the use of quantitative neuromuscular monitoring was associated with a reduced incidence of postoperative residual neuromuscular block, compared with qualitative (subjective) monitoring, or no monitoring at all (11.5 versus 30.6 versus 33.1 percent, respectively) [<a href="#rid74">74</a>]. However, the quality of evidence was judged to be very low.</p><p class="headingAnchor" id="H2741898606"><span class="h2">Strategy for avoiding residual block</span><span class="headingEndMark"> — </span>A suggested strategy for avoidance of residual neuromuscular blockade is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Use intermediate or short acting NMBAs, rather than long acting NMBAs (eg, <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">pancuronium</a>) whenever possible</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid deep neuromuscular blockade (ie, train-of-four count [TOFC] = 0, post tetanic count &gt;1) when clinically appropriate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use objective neuromuscular monitoring whenever possible to guide administration of NMBAs and assess recovery of neuromuscular function for all patients who receive NMBAs</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If only a peripheral nerve stimulator is available, ensure electrode placement is not causing direct muscle stimulation  (<a class="graphic graphic_figure graphicRef114145" href="/d/graphic/114145.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef114147" href="/d/graphic/114147.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid monitoring facial muscles as this will overestimate the degree of recovery. If the arms are not accessible due to surgical positioning, monitor the facial muscles but transition to the arms once they become available. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade", section on 'Nerves that may be monitored'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer reversal agents in appropriate doses, and guided by the degree of recovery from neuromuscular block  (<a class="graphic graphic_table graphicRef114082" href="/d/graphic/114082.html" rel="external">table 6</a>). (See <a class="local">'Reversal of neuromuscular block'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer no reversal agents if adequate spontaneous recovery has been achieved, as demonstrated by a quantitative TOFR &gt;0.9.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>, in appropriate doses, only if spontaneous recovery has reached a TOFC = 4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If spontaneous recovery has not reached a TOFC = 4 (as assessed at the adductor pollicis muscle), use <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> rather than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> for reversal of steroidal NMBAs. If sugammadex is unavailable (or if using benzylisoquinolinium NMBAs), wait for spontaneous recovery to achieve a TOFC = 4 before administering neostigmine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extubate the trachea only after a TOFR ≥0.9 is achieved (when objective monitors are available).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a quantitative monitor is not available, administer <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> only when TOFC = 4 (as assessed at the adductor pollicis muscle) and allow adequate time for full reversal of neuromuscular blockade, at least 10 minutes after neostigmine administration, before tracheal extubation [<a href="#rid75">75,76</a>]. (See <a class="local">'Anticholinesterases'</a> below.)</p><p></p><p class="bulletIndent1">As the operation nears completion, allow the patient to recover to a TOFC of 4 by the time the surgeon starts to close the wound. When <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> is administered at this time, one would expect to be ready to extubate the trachea in 10 minutes or so, once the drapes are coming down. If the patient moves or became dyssynchronous with the ventilator near the end of the operation, administer <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> rather than NMBA. This timing requires familiarity with the surgeon and each individual practice.</p><p></p><p>These recommendations are consistent with 2023 guidelines from the American Society of Anesthesiologists  (<a class="graphic graphic_table graphicRef140502" href="/d/graphic/140502.html" rel="external">table 7</a>) [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H154268994"><span class="h1">REVERSAL OF NEUROMUSCULAR BLOCK</span><span class="headingEndMark"> — </span>A train-of-four ratio (TOFR) ≥0.9 should be achieved prior to tracheal extubation following administration of NMBAs [<a href="#rid78">78</a>]. Reversal of neuromuscular block after administration of NMBAs can occur by spontaneous recovery, or by administration of reversal agents. Reversal agents include anticholinesterases and <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>, the only available selective relaxant reversal agent, which is specific for aminosteroid nondepolarizing NMBAs.</p><p>The recommended doses of the commonly used reversal agents and the time course of recovery from various levels of rocuronium-induced neuromuscular block are shown in a table  (<a class="graphic graphic_table graphicRef114082" href="/d/graphic/114082.html" rel="external">table 6</a>).</p><p>Reversal agents can rarely cause adverse effects that require treatment (bradycardia, bronchospasm, and very rarely anaphylaxis or cardiac arrest). Thus we strongly recommend physiologic monitoring and vigilance throughout emergence from anesthesia whenever reversal agents are used. (See <a class="local">'Sugammadex versus neostigmine'</a> below.)</p><p class="headingAnchor" id="H3662862510"><span class="h2">Spontaneous recovery</span><span class="headingEndMark"> — </span>Reversal agents should only be omitted when clinicians can confirm adequate recovery from neuromuscular blockade to a TOFR of 0.9 or greater using quantitative monitoring. The response to single intubating doses of NMBAs is variable among patients and responses can be difficult to predict. As an example, a large trial found that after a single intubating dose of an intermediate-acting NMBA, 37 percent of patients had not spontaneously recovered to a TOFR of 0.9 two hours after administration [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H1667432385"><span class="h2">Anticholinesterases</span><span class="headingEndMark"> — </span>Anticholinesterase agents work by increasing the availability of acetylcholine at the neuromuscular junction, to compete with nondepolarizing NMBAs for nicotinic acetylcholine receptors (nAChRs) and restore neuromuscular transmission. The anticholinesterases available for reversal of NMBA are <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> and <a class="drug drug_general" data-topicid="9403" href="/d/drug information/9403.html" rel="external">edrophonium</a>. Neostigmine is usually preferred, despite a slower onset of action than edrophonium, because neostigmine has higher affinity for acetylcholine receptors. Both drugs have a duration of action of 60 to 120 minutes [<a href="#rid80">80</a>].</p><p>Blockade of cholinesterase occurs at all cholinergic sites, including muscarinic receptors, such that these drugs have parasympathomimetic effects. Therefore, anticholinergic, antimuscarinic drugs (ie, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> or <a class="drug drug_general" data-topicid="8496" href="/d/drug information/8496.html" rel="external">glycopyrrolate</a>) are administered along with anticholinesterases to prevent bradycardia and gastrointestinal side effects.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">Neostigmine</a><strong> </strong>–<strong> </strong>Neostigmine is the anticholinesterase agent most commonly used for reversal of neuromuscular blockade. <a class="drug drug_general" data-topicid="8496" href="/d/drug information/8496.html" rel="external">Glycopyrrolate</a> is routinely administered along with neostigmine (0.2 mg glycopyrrolate IV for each 1 mg neostigmine IV) as they have a similar onset of action.</p><p></p><p class="bulletIndent1">The rate of reversal of neuromuscular block with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> is variable. Factors that affect the speed of reversal include the depth of existing block, the dose of neostigmine, and the other factors that can affect the degree of neuromuscular block (eg, inhalation anesthesia, hypothermia, acidosis, electrolyte disturbances, hypercarbia, patient age) [<a href="#rid81">81,82</a>]. (See <a class="local">'Factors that affect the response to neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1">Reversal of neuromuscular block with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> takes longer during inhalation anesthesia than during intravenous (IV) anesthesia with <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>. In one study, 160 patients were randomly assigned to maintenance of anesthesia with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> or propofol, and reversal of <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> with neostigmine at different levels of block. The median time from administration of neostigmine at a train-of-four count (TOFC) of 3 to recovery to a TOFR of 0.9 was 15.6 minutes (7.3 to 43.9) during sevoflurane anesthesia and was 5.4 minutes (1.6 to 8.6) during propofol anesthesia [<a href="#rid82">82</a>]. The median time to recovery if neostigmine was administered at TOFC of 4 was 9.7 minutes (5.1 to 26.4) during sevoflurane anesthesia, and 4.7 minutes (1.3 to 7.2) during propofol anesthesia.</p><p></p><p class="bulletIndent1">If sufficient spontaneous recovery (train-of-four [TOF] &gt;0.9) can be confirmed through quantitative monitoring, <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> is unnecessary. If quantitative monitoring is not available or this level of recovery has not been achieved, neostigmine (or <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>) should be administered in an appropriate dose based on the degree of neuromuscular block at the time of administration  (<a class="graphic graphic_table graphicRef114082" href="/d/graphic/114082.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">Neostigmine</a> is ineffective at reversing deep levels of neuromuscular blockade (TOFC = 0, post-tetanic count [PTC] ≥1, TOFC = 0) [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">Neostigmine</a> should be administered at a TOFC of 4 (shallow levels of blockade) [<a href="#rid83">83</a>], and the patient should be extubated no sooner than 10 minutes after administration of neostigmine. At a TOFC of 4, neostigmine doses of 20 to 50 mcg/kg may be sufficient to effect adequate recovery [<a href="#rid84">84</a>]. Higher doses than these are no more effective, and increase the risk of a direct neuromuscular blocking effect of the drug. A reduced dose of 15 to 30 mcg/kg may be used if there is minimal block using an objective neuromuscular monitor (ie, TOFR &gt;0.4 and &lt;0.9) or if there is a TOFC of 4 without fade using a peripheral nerve stimulator  (<a class="graphic graphic_table graphicRef114083" href="/d/graphic/114083.html" rel="external">table 8</a>) [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient has a TOFC of 1 to 3 at the conclusion of an operation, wait for spontaneous recovery to TOFC of 4 prior to administration of <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If reversal is inadequate after the initial dose of <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>, additional neostigmine may be administered up to a total dose of 70 mcg/kg (maximum 5 mg) IV. If <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> was used, it is reasonable to administer <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> 1 or 2 mg/kg IV in this setting, preferably guided by quantitative neuromuscular monitoring. (See <a class="local">'Sugammadex'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The use of <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> in the absence of NMBAs can result in paradoxical neuromuscular weakness [<a href="#rid85">85,86</a>]. Administration of neostigmine during recovery from neuromuscular blockade, even at TOFR &gt;0.9, is unlikely to result in clinically significant weakness. It appears that nAChR occupancy by the remaining nondepolarizing molecules provides a protective effect from the depolarizing actions of excess acetylcholine. This was demonstrated by a study in which 90 anesthetized patients who had recovered to a TOFR &gt;0.9 after a single dose of <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> were randomly assigned to receive neostigmine 40 mcg/kg IV or <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> [<a href="#rid87">87</a>]. There were no differences in TOFR five minutes after reversal or on admission to the postanesthesia care unit, and no differences in postoperative weakness, hypoxemia, or airway obstruction. Neostigmine-induced decrements in neuromuscular function should almost <strong>never</strong> occur clinically [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9403" href="/d/drug information/9403.html" rel="external">Edrophonium</a><strong> </strong>–<strong> </strong>Edrophonium has a faster onset (one to two minutes) than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> and is usually coadministered with <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> (7 to 14 mcg/kg IV), which has a similar onset of action, to block antimuscarinic effects. Binding of edrophonium to acetylcholinesterases is much weaker than the neostigmine, and it should only be used at shallow levels of neuromuscular blockade. The standard dose of 0.5 to 1 mg/kg results in a similar duration of antagonism as neostigmine [<a href="#rid80">80</a>].</p><p></p><p class="headingAnchor" id="H3132576103"><span class="h2">Sugammadex</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> is a gamma-cyclodextrin that encapsulates and subsequently inactivates steroidal NMBAs. Affinity is greatest for <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, followed in decreasing order of affinity by <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, and <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">pancuronium</a> [<a href="#rid88">88</a>]. Sugammadex has no effect on <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> or the benzylisoquinolinium NMBAs.</p><p>After administration, binding occurs in plasma, leading to a rapid decrease in the plasma levels of unbound NMBA molecules. This results in a concentration gradient between the free NMBA molecules at the neuromuscular junction (NMJ) and in the plasma, leading to a net transfer of unbound NMBA back into the plasma, where it is encapsulated by unbound <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>. This rapid decrease in free NMBA at the NMJ results in rapid and effective antagonism and restoration of normal transmission and neuromuscular function. Sugammadex reversal produces a more complete and faster recovery than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> or <a class="drug drug_general" data-topicid="9403" href="/d/drug information/9403.html" rel="external">edrophonium</a> reversal [<a href="#rid89">89-91</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– The dose of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> should be based on the level of neuromuscular block.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At a deep level of neuromuscular blockade (TOFC = 0, PTC 1 to 2), a dose of 4 mg/kg results in recovery to a TOFR ≥0.9 within five minutes [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At a TOFC 2 to 4 a dose of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> of 2 mg/kg IV results in a TOFR ≥0.9 in three to four minutes [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In emergency situations in which intubation and ventilation are unexpectedly difficult or impossible, 16 mg/kg <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> can reverse profound rocuronium-induced blockade within three minutes [<a href="#rid94">94</a>]. Whereas rapid reversal of neuromuscular block may be helpful in this setting, a number of other factors may affect the restoration of spontaneous ventilation (eg, coadministered anesthetics and opioids, patient factors). (See  <a class="medical medical_review" href="/d/html/90615.html" rel="external">"Management of the difficult airway for general anesthesia in adults", section on 'The failed airway'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If reversal of aminosteroid induced block (ie, after <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>) is inadequate after administration of up to 70 mcg/kg or 5 mg IV of <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>, it is reasonable to administer 1 to 2 mg/kg <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> IV, guided by quantitative neuromuscular monitoring. Optimal dosing of sugammadex in this setting has not been determined.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Importantly, the response to the doses of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> based on the TOFC may vary. Quantitative monitoring should be used to confirm adequate reversal prior to extubation, even when reversing with sugammadex, as residual weakness is still possible. This was demonstrated in a single-center prospective dose-finding study in 97 patients who underwent cardiac surgery and received sugammadex for reversal of rocuronium-induced neuromuscular block [<a href="#rid95">95</a>]. After receiving the manufacturer recommended doses (which are described above), 13 percent of patients had residual weakness (ie, TOFR &lt;0.9), and two patients had recurrent paralysis.</p><p></p><p class="bulletIndent1">Administration of excessive doses of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> should be avoided, because the incidence of anaphylaxis with sugammadex is proportional to the dose administered [<a href="#rid96">96</a>], excessive administration may prevent or delay subsequent reestablishment of neuromuscular block with steroidal NMBAs, and sugammadex is expensive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elimination</strong> – The sugammadex-NMBA complex is excreted in the urine unchanged [<a href="#rid97">97</a>]. <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> is not approved by the US Food and Drug Administration (FDA) for patients with severe renal impairment, primarily due to concerns about the possibility of recurrence of paralysis if the complex dissociates. There is also concern that prolonged exposure to sugammadex could increase the risk of anaphylaxis. However, a multicenter retrospective review of 158 surgical patients with end-stage kidney disease who received sugammadex reversal reported no cases of recurrence of neuromuscular blockade, and no cases of anaphylaxis [<a href="#rid98">98</a>]. In 24 patients, sugammadex was used effectively to reverse neuromuscular blockade after inadequate reversal with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>. Similarly, a retrospective review of 219 patients with end stage renal disease who received sugammadex for reversal, there were no postoperative complications attributed to the use of sugammadex [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions </strong>– <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> can bind and inhibit oral contraceptives. Patients should use alternative contraceptive techniques for seven days after exposure to sugammadex [<a href="#rid100">100</a>]. Reestablishing neuromuscular blockade with steroidal NMBA within three hours of sugammadex administration requires increased doses [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> has been associated with several types of adverse events.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypersensitivity reactions</strong> – <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> has increasingly been implicated as a cause of perioperative anaphylaxis. The incidence of anaphylaxis after exposure to sugammadex is unclear, and has been reported to occur in 1:3500 to 1:64,000 exposures. (See  <a class="medical medical_review" href="/d/html/2081.html" rel="external">"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions", section on 'Sugammadex'</a>.)</p><p></p><p class="bulletIndent2">Drug hypersensitivity reactions are the result of immune or inflammatory cell stimulation by the drug, and may present during anesthesia with flushing; rash; urticaria; angioedema of the face, extremities, or larynx; wheezing; and/or hypotension. Anaphylaxis is the most severe form of immediate hypersensitivity reaction. The diagnosis is clinical and based on rapid onset and progression of signs and symptoms that typically include hypotension, bronchospasm, laryngeal edema, and tachycardia. Classification and clinical manifestations of drug hypersensitivity are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features"</a> and  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Clinical manifestations and diagnosis'</a>.)</p><p></p><p class="bulletIndent2">Hypersensitivity reactions to <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> typically appear rapidly after IV administration (ie, usually within a minute but sometimes up to several minutes later) and can occur with first-time administration. Risk factors have not been identified, though the incidence of some types of reactions appears to be dose dependent [<a href="#rid102">102</a>]. Reactions can involve clinically significant airway edema and bronchospasm, and if this develops after tracheal extubation, reintubation may be required. Hypersensitivity reactions and anaphylaxis to sugammadex are discussed in several other topics. (See  <a class="medical medical_review" href="/d/html/2081.html" rel="external">"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions", section on 'Sugammadex'</a> and  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Sugammadex'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac arrhythmias </strong>–<strong> </strong>Cardiac arrhythmias, including marked bradycardia and asystole, may occur after administration of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> [<a href="#rid103">103</a>]. Thus, full electrocardiogram (ECG) monitoring should be continued during and after administration of sugammadex, and <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> and other vasoactive drugs should be immediately available [<a href="#rid104">104</a>]. From 2009 to 2017, 138 cases of serious cardiac adverse events with nine deaths after administration of sugammadex were reported to the US Food and Drug Administration adverse events reporting system, including bradycardia (n = 66), cardiac arrest (n = 39), ventricular fibrillation (n = 10), and ventricular tachycardia (n = 8) [<a href="#rid105">105</a>]. The reported incidence of sugammadex-induced bradycardia is approximately 1 percent [<a href="#rid106">106</a>], and the etiology is unknown. While sugammadex-induced bradycardia is typically transient, it has precipitated cardiac arrest and hemodynamic collapse in some cases [<a href="#rid103">103,106,107</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – Small increases in coagulation parameters have been reported after <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> administration, but clinically significant bleeding has not been reported [<a href="#rid108">108</a>]. There have been several reports of laryngospasm that occurred near the time of sugammadex administration [<a href="#rid109">109-111</a>]. While a direct causal relationship has not been established, vigilance is warranted in maintaining airway patency as neuromuscular function is restored.</p><p></p><p class="headingAnchor" id="H9271260"><span class="h2">Sugammadex versus neostigmine</span><span class="headingEndMark"> — </span>For patients who receive steroidal NMBAs (eg, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>) and require reversal, we suggest using <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> rather than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>. However, sugammadex is significantly more expensive than neostigmine. Where cost is an issue, it is reasonable to restrict the use of sugammadex to patients who are at higher risk of complications of postoperative residual neuromuscular block (eg, patients &gt;80 years of age or who undergo thoracic surgery), and/or patients who need reversal from TOFC ≤3.</p><p>Benefits of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> compared with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> reverses neuromuscular blockade more quickly and reliably than <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>, and can be used to reverse deeper levels of block [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> reversal is associated with reduced incidence of residual neuromuscular blockade [<a href="#rid112">112,113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">Sugammadex</a> reversal probably reduces postoperative pulmonary complications, particularly in high risk patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a single institution randomized trial of 180 high risk older adults (ASA physical status 3 or 4, ≥75 years of age) who underwent nonemergency surgery with <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> induced neuromuscular blockade, there was a trend towards improved postoperative pulmonary outcomes in patients who received <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>, though the results did not reach statistical significance [<a href="#rid114">114</a>]. The rate of radiograph confirmed pneumonia within seven days was lower in patients who received sugammadex (2.4 versus 9.6 percent), though the number of events was small. Conclusions are limited by the timing of reversal; the agents were administered at a deeper level of block than we recommend when using <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> (four twitches with TOF monitoring, TOFR ≥0.4). (See <a class="local">'Anticholinesterases'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multicenter matched cohort study of over 45,000 surgical patients, compared with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>, reversal with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> was associated with a lower incidence of pneumonia (1.3 versus 2.2 percent, odds ratio [OR] 0.7 [95% CI 0.44-0.62]) and reduced risk of respiratory failure (0.8 versus 1.7 percent, OR 0.45 [95% CI 0.37-0.56]) [<a href="#rid115">115</a>]. Median patient age was 58 years; 55 percent were ASA physical status 3.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In contrast, in a single institution cohort study that compared the incidence of postoperative pulmonary complications (PPCs) before and after an institutional change from using <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> to using <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> for routine reversal of NMBAs, the incidence of PPCs was similar before and after the switch [<a href="#rid116">116</a>]. Conclusions from this study are limited by the possibility of other practice changes over time, and inconsistency or absence of data on neuromuscular monitoring.</p><p></p><p>Serious intraoperative adverse effects and complications of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> and <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> are rare, and both drugs appear to be similarly safe. This is supported by a single institution retrospective review of clinically important adverse events in approximately 90,000 patients who underwent general, cardiac, or pediatric surgery and who received sugammadex or neostigmine for reversal of neuromuscular blockade at the end of surgery [<a href="#rid117">117</a>]. The incidence of a composite outcome of adverse events requiring pharmacologic intervention (ie, bradycardia, anaphylaxis, bronchospasm, and cardiac arrest) was slightly higher with sugammadex (3.4 percent) than neostigmine (3.0 percent), based primarily on differences in bronchospasm and bradycardia, which are usually easily treated. Anaphylaxis and cardiac arrest were extremely rare with both drugs (0.004 to 0.02 percent). The difference in the composite outcome resulted in a number needed to harm of 250 patients, meaning 250 patients would need to be given neostigmine rather than sugammadex to avoid one of these events.</p><p>In a meta-analysis of 10 randomized trials (959 patients) that compared NMBA reversal with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> versus <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a>, there was no significant difference in the incidence of one or more serious adverse event or a composite of serious adverse events [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H3484879739"><span class="h1">CLASSIFICATION OF NEUROMUSCULAR BLOCKING AGENTS</span><span class="headingEndMark"> — </span>NMBAs are classified according to their interaction with nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction (NMJ). <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a>, the only depolarizing NMBA in use, produces skeletal muscle relaxation by binding directly with nAChRs to cause prolonged depolarization. Nondepolarizing NMBAs act as competitive antagonists (competing with acetylcholine [ACh] for the binding sites at the nAChRs), preventing the initiation of action potential. The type of neuromuscular block determines the response to peripheral nerve stimulation used for monitoring the effects of NMBAs. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade"</a>.)</p><p>The NMJ consists of the presynaptic motor neuron, a synaptic cleft or gap, and the postsynaptic surface of the myocyte  (<a class="graphic graphic_figure graphicRef114133" href="/d/graphic/114133.html" rel="external">figure 4</a>) [<a href="#rid15">15</a>]. As an electrical signal in a motor nerve reaches the presynaptic nerve terminal, depolarization occurs, and acetylcholine (ACh) is released via calcium channel-mediated exocytosis into the synaptic cleft. This cleft is home to acetylcholinesterase, the enzyme that breaks down ACh. Fifty percent of the released ACh is cleaved by acetylcholinesterase, and the remaining molecules bind to postsynaptic nAChRs on the motor end plate, which causes ion channels to open. When enough channels are opened, the myocyte is depolarized and muscle contraction occurs. Acetylcholine remaining in the synapse is rapidly degraded by acetylcholinesterase, and the muscle is allowed to repolarize.</p><p class="headingAnchor" id="H370576226"><span class="h1">SUCCINYLCHOLINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> (also known as diacetylcholine or suxamethonium chloride) is the only depolarizing NMBA available for clinical use.</p><p class="headingAnchor" id="H2517648691"><span class="h2">Pharmacology of succinylcholine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> produces a reliable neuromuscular blockade that is the fastest in onset and shortest in duration of all NMBAs. Thus succinylcholine is often used for rapid sequence induction and intubation. (See  <a class="medical medical_review" href="/d/html/94214.html" rel="external">"Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Succinylcholine'</a> and <a class="local">'Endotracheal intubation'</a> above.)</p><p>Within 30 seconds after intravenous (IV) administration, patients experience fasciculations from depolarization and antidromic activation of unparalyzed portions of the motor unit [<a href="#rid118">118</a>]; flaccid paralysis ensues seconds later. Fasciculations of varying duration and intensity occur in 94 percent of patients [<a href="#rid119">119</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing/onset of action</strong> – An IV dose of 1 to 1.5 mg/kg, or 3 to 5 x ED<sub>95</sub>,<sub> </sub>yields flaccid paralysis in one to two minutes. After an intubating dose, the clinical duration of action (defined as the time from drug administration until recovery of single twitch to 25 percent of baseline) is 7 to 12 minutes. If IV access is unavailable, <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> can also be administered intramuscularly (3 to 4 mg/kg), and paralysis will occur in approximately four minutes.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> is occasionally administered by infusion, titrated to twitch depression, most often when a brief period of neuromuscular blockade is required (such as electroconvulsive therapy). Use of a succinylcholine infusion or by repeated bolus administration increase the risk of Phase II block, and prolonged paralysis. Phase II block usually occurs after total succinylcholine doses exceeding 4 mg/kg. Alternatives to succinylcholine infusion for short procedures include mivacurium (where available), or intermediate duration steroidal NMBAs (ie, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>) followed by reversal with <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>. (See <a class="local">'Mivacurium'</a> below and <a class="local">'Sugammadex'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> – <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> is metabolized by butyrylcholinesterase (also known as pseudocholinesterase or plasma cholinesterase) in a process that yields no active metabolites.</p><p></p><p class="headingAnchor" id="H1229187692"><span class="h3">Phase II block</span><span class="headingEndMark"> — </span>Phase II block typically develops after large doses of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> (&gt;4 mg/kg), after repeated doses, or after a continuous infusion; some characteristics of phase II block have been described in doses as low as 0.3 mg/kg [<a href="#rid120">120</a>]. This type of block occurs when the post-junctional membrane action potential eventually returns to baseline, despite the continued activation of nAChRs in the presence of succinylcholine. Phase II block is associated with some of the features of nondepolarizing block, including train-of-four (TOF) fade and post-tetanic potentiation.</p><p class="headingAnchor" id="H2104230870"><span class="h3">Butyrylcholinesterase (pseudocholinesterase) deficiency</span><span class="headingEndMark"> — </span>In patients with atypical or deficient butyrylcholinesterase, recovery from <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> (and mivacurium) can be prolonged. A variety of factors can reduce butyrylcholinesterase activity but only modestly prolong paralysis with succinylcholine, including liver disease, pregnancy, advanced age, renal failure, major burns, oral contraceptives, and <a class="drug drug_general" data-topicid="9398" href="/d/drug information/9398.html" rel="external">echothiophate</a> eye drops. In contrast, abnormal genetic variants of the butyrylcholinesterase enzyme can cause marked prolongation of paralysis after succinylcholine administration. Duration of paralysis may be increased by 50 to 100 percent in patients who are heterozygous for abnormal butyrylcholinesterase. Patients who are homozygous for the abnormal gene may be paralyzed for up to eight hours after an intubating dose of succinylcholine, and may require prolonged postoperative mechanical ventilation [<a href="#rid121">121</a>].</p><p>Atypical butyrylcholinesterase is often diagnosed after a patient has an unexpectedly prolonged response to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. Objective TOF monitoring should be used, and recovery documented prior to extubation, for all patients who have received NMBAs, including those who have received succinylcholine. Some degree of recovery from succinylcholine-induced block should be documented prior to administration of a nondepolarizing NMBA, as administration of a nondepolarizing NMBA prior to documenting recovery from succinylcholine will complicate evaluation and subsequent management, should prolonged succinylcholine block occur. Principles for management of prolonged block after succinylcholine should include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Causes for prolonged block other than butyrylcholinesterase deficiency should be ruled out, including hypothermia and electrolyte disorders, or malfunctioning of the peripheral nerve stimulator or neuromuscular monitor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TOF fade is indicative of phase II block that is likely to occur in these patients. Reversal with <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> should <strong>not</strong> be attempted. Anticholinesterase agents can worsen paralysis and induce phase II block in this setting. Lack of fade may indicate resolution of phase II block, but the degree of recovery from phase I block cannot be assessed without a baseline, pre-NMBA twitch.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient should be sedated and mechanically ventilated until full return of muscle strength as determined by quantitative monitoring if available. If quantitative monitoring is not available, the subjective monitoring with a peripheral nerve stimulator is warranted to confirm recovery.</p><p></p><p>After an episode of prolonged paralysis after <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, testing may be performed for the level and activity of butyrylcholinesterase. These tests are not routinely performed in hospital laboratories, and blood samples are usually sent to specialized testing centers. Two tests are performed, one for the level of enzyme activity, and if enough activity exists, another test is performed for the <a class="drug drug_general" data-topicid="8894" href="/d/drug information/8894.html" rel="external">dibucaine</a> number, which indicates the percent of inhibition of the enzyme under standardized test conditions. The blood sample for these tests should be drawn after the patient has recovered full muscle strength, since the enzyme activity results can vary depending on anesthetic exposure [<a href="#rid122">122</a>]. Dibucaine inhibition (ie, phenotype testing) is not affected by anesthetic exposure.</p><p><a class="drug drug_general" data-topicid="8894" href="/d/drug information/8894.html" rel="external">Dibucaine</a> inhibition of 70 to 80 percent indicates a normal enzyme, whereas dibucaine inhibition of 20 to 30 percent indicates a homozygous atypical enzyme.</p><p class="headingAnchor" id="H996697223"><span class="h2">Adverse effects of succinylcholine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> is associated with a number of adverse effects, many of which are related to its depolarizing effect. Succinylcholine is contraindicated for patients with susceptibility to malignant hyperthermia, denervating conditions, major burns after 48 hours, and severe hyperkalemia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperkalemia</strong> – Serum potassium levels increase by approximately 0.5 mEq/L after the administration of 1 mg/kg <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. This increase is exaggerated and may be life-threatening in patients who have upregulation of extrajunctional nicotinic acetylcholine receptors (nAChRs; eg, stroke with paralysis, spinal cord injury, muscle and muscle membrane disorders, muscular sclerosis, and polyneuropathies, sepsis, prolonged bed rest), or significant burns [<a href="#rid123">123,124</a>]. The administration of a small dose of a nondepolarizing NMBA prior to succinylcholine (ie, a defasciculating dose) does not reliably prevent the rise in potassium associated with succinylcholine.</p><p></p><p class="bulletIndent1">Administration of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> for routine intubation in children has largely been abandoned. The Food and Drug Administration of the United States has issued a boxed warning for succinylcholine for children, except for emergency airway management, over concerns for acute rhabdomyolysis and hyperkalemia in children with undiagnosed muscular dystrophies. Despite the warning, succinylcholine can be used in carefully screened children in select circumstances (eg, for rapid sequence induction and intubation [RSII]). (See  <a class="medical medical_review" href="/d/html/106984.html" rel="external">"General anesthesia in neonates and children: Agents and techniques", section on 'Intravenous induction medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant hyperthermia</strong> – <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> is a known trigger for malignant hyperthermia (MH), and its use is contraindicated in patients at risk for MH. (See  <a class="medical medical_review" href="/d/html/403.html" rel="external">"Susceptibility to malignant hyperthermia: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myalgias</strong> – Nearly one-half of patients experience myalgias after receiving <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. Such myalgias were initially thought to be related to the fasciculations. However, the use of a nondepolarizing NMBA or "defasciculating" dose may attenuate, but does not reliably prevent, myalgias [<a href="#rid15">15</a>]. Nonsteroidal anti-inflammatory drugs are the most effective means of attenuating succinylcholine-induced myalgias (number-needed-to-treat of 2.5 to 3), but only prevent myalgia in one-third of patients [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1">Pretreatment with nondepolarizing NMBAs can produce partial neuromuscular blockade, which results in visual disturbances, difficulty breathing, and other adverse effects [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased intragastric pressure</strong> – While <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> increases intragastric pressure, the risk of aspiration is mitigated by a simultaneous increase in the lower esophageal sphincter tone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased intraocular pressure</strong> – <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> can cause increased intraocular pressure by up to 15 mmHg via unknown mechanisms. The optimal strategy for RSII in the setting of an open eye with a full stomach is debated, and must be individualized. (See  <a class="medical medical_review" href="/d/html/96505.html" rel="external">"Anesthesia for emergency eye surgery", section on 'Induction of anesthesia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased intracranial pressure</strong> – <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> can produce a transient increase in intracranial pressure, which can be attenuated by administration of a defasciculating dose of nondepolarizing NMBA. (See  <a class="medical medical_review" href="/d/html/93391.html" rel="external">"Anesthesia for craniotomy in adults", section on 'Neuromuscular blocking agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac dysrhythmias</strong> – <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> may cause a variety of arrhythmias [<a href="#rid125">125</a>]. Bradycardia is the most common of these, and occurs most frequently in children, or with repeated administration. Some clinicians routinely administer <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> prior to RSII with succinylcholine in children to prevent bradycardia or asystole. (See  <a class="medical medical_review" href="/d/html/106984.html" rel="external">"General anesthesia in neonates and children: Agents and techniques", section on 'Rapid sequence induction and intubation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic reactions</strong> – NMBAs are among the commonly implicated triggers for perioperative anaphylaxis. The reported incidence of anaphylaxis varies, but it appears that the rates of anaphylaxis to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> and <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> are significantly higher than the rates of reaction to other NMBAs [<a href="#rid126">126</a>]. (See  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Neuromuscular-blocking agents'</a>.)</p><p></p><p class="headingAnchor" id="H3507460328"><span class="h1">NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS</span><span class="headingEndMark"> — </span>Nondepolarizing, competitive NMBAs are classified by their chemical structure (steroidal versus benzylisoquinolinium) as well as their duration of action (short-, intermediate-, or long-acting agents). The properties of NMBAs are shown in tables  (<a class="graphic graphic_table graphicRef114207" href="/d/graphic/114207.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef114210" href="/d/graphic/114210.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef114271" href="/d/graphic/114271.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H1229812700"><span class="h2">Pharmacology of nondepolarizing neuromuscular blocking agents</span><span class="headingEndMark"> — </span>In general, the speed of onset of neuromuscular block depends on the potency of the drug; greater potency is associated with slower onset of block. Thus, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, with an ED<sub>95</sub> of 0.3 mg/kg IV, has a much more rapid onset than <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, which has an ED<sub>95</sub> of 0.05 mg/kg  (<a class="graphic graphic_table graphicRef114207" href="/d/graphic/114207.html" rel="external">table 4</a>). The standard intubating dose of nondepolarizing NMBAs is 2 to 3 times the ED<sub>95</sub> for the specific drug. Higher doses of some drugs speed onset of block and may be used for rapid sequence induction and intubation (RSII), though with a prolonged duration of block.</p><p>A dose of 10 percent of the ED<sub>95 </sub>may be utilized to maintain an existing level of neuromuscular block during anesthesia, guided by neuromuscular monitoring. (See <a class="local">'Facilitation of surgery'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steroidal compounds </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">Rocuronium</a> and <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> are intermediate-acting, steroidal NMBAs. <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">Pancuronium</a> is the only available long-acting steroidal NMBA; it is no longer available in the United States, Canada, or Europe, but is available in several countries around the world. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzylisoquinolinium compounds </strong>–<strong> </strong>Mivacurium is the only short-acting, benzylisoquinolinium NMBA. It is no longer available in the United States, but is available in some other countries.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">Atracurium</a> and its isomer <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a> are two intermediate-acting benzylisoquinolinium NMBAs. Curare (d-Tubocurarine) is a long-acting benzylisoquinolinium NMBA that is not available in North America.</p><p></p><p class="headingAnchor" id="H3502991180"><span class="h2">Steroidal neuromuscular blocking agents</span></p><p class="headingAnchor" id="H874124449"><span class="h3">Rocuronium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">Rocuronium</a> has a faster onset than other nondepolarizing NMBAs. Thus rocuronium may be used at higher doses as an alternative to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> for RSII. (See  <a class="medical medical_review" href="/d/html/271.html" rel="external">"Induction agents for rapid sequence intubation in adults for emergency medicine and critical care"</a>.)</p><p><a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">Rocuronium</a> does not release histamine, nor is it vagolytic, and it causes minimal hemodynamic effects. The incidence of allergic reactions to rocuronium and <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> appears to be higher than other NMBAs. (See  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Neuromuscular-blocking agents'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing/onset of action </strong>– The standard intubating dose of 0.6 mg/kg (2 x ED<sub>95</sub>) provides adequate intubating conditions in 1.5 to 3 minutes in most (but not all) patients. (See <a class="local">'Endotracheal intubation'</a> above.)</p><p></p><p class="bulletIndent1">After an intubating dose, the clinical duration of action is 30 to 70 minutes. Thereafter, doses of 0.1 mg/kg or an infusion at a dose of 5 to 12 mcg/kg/minute can be used to maintain neuromuscular blockade, guided by neuromuscular monitoring. The RSII dose of <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> of 1.2 mg/kg, or 4 x ED<sub>95</sub>,<sub> </sub>has a similar average onset time as <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, although the variability in onset is greater with rocuronium [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics </strong>– <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">Rocuronium</a> has a volume of distribution of 0.3 to 0.7 L/kg. It is excreted mostly through the biliary route, although a small portion is excreted renally. Its metabolism results in 17-desacetyl-rocuronium, a compound that has 20 percent the activity of the parent compound.</p><p></p><p class="headingAnchor" id="H3496358285"><span class="h3">Vecuronium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">Vecuronium</a> is a steroidal NMBA with minimal hemodynamic effects. It is not used as an alternative to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> for RSII because of slower onset time compared with <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing/onset of action</strong> – An intubating dose of <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> of 0.1 mg/kg, or 2 x ED<sub>95 </sub>provides adequate intubating conditions in three to four minutes. The maintenance dose is 0.01 mg/kg, or an infusion at 1 to 2 mcg/kg/min, guided by neuromuscular monitoring. Following an intubating dose, the clinical duration of action is 25 to 50 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> – <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">Vecuronium</a> has a volume of distribution of 0.4 L/kg. It is excreted both through the biliary and renal routes. Thus patients with renal or hepatic disease may have a prolonged response to vecuronium, and maintenance doses should be carefully guided by neuromuscular monitoring. Vecuronium is metabolized to 3-desacetyl-vecuronium, a compound that has 60 percent the activity of the parent compound.</p><p></p><p class="headingAnchor" id="H744534214"><span class="h3">Pancuronium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">Pancuronium</a> (no longer available in North America or Europe) is a long-acting steroidal NMBA that is rarely used because of a high incidence of postoperative residual neuromuscular weakness. Pancuronium can cause tachycardia as a result of direct sympathomimetic stimulation and blockade of cardiac muscarinic receptors [<a href="#rid128">128</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing/onset of action </strong>– An intubating dose of <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">pancuronium</a> of 0.1 mg/kg (1.5 x ED<sub>95</sub>) provides adequate intubating conditions in three to five minutes. The maintenance dose is 0.02 mg/kg. Following an intubating dose, the clinical duration of action is 60 to 120 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics </strong>– <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">Pancuronium</a> has a volume of distribution of 0.2 to 0.3 L/kg. It is eliminated mostly through the renal route, with approximately 20 percent biliary excretion. Pancuronium is metabolized to 17-OH-pancuronium and 3-OH- pancuronium, with the latter possessing 50 percent the activity of the parent compound. Pancuronium should generally be avoided in patients with renal and hepatic impairment. If necessary, maintenance doses should be carefully guided by neuromuscular monitoring.</p><p></p><p class="headingAnchor" id="H830025861"><span class="h2">Benzylisoquinolinium neuromuscular blocking agents</span></p><p class="headingAnchor" id="H3215606083"><span class="h3">Atracurium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">Atracurium</a> is an intermediate-acting benzylisoquinolinium NMBA that is a mixture of 10 isomers.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing/onset of action </strong>– An intubating dose of <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a> of 0.5 mg/kg, or 2 x ED<sub>95</sub> provides adequate intubating conditions in three to five minutes. The maintenance dose of atracurium is 0.1 mg/kg, or an infusion at 10 to 20 mcg/kg/min, guided by neuromuscular monitoring. At doses higher than 0.5 mg/kg, atracurium increases plasma histamine levels, causing skin flushing, hypotension, and tachycardia [<a href="#rid129">129</a>]. Following an intubating dose, the clinical duration of atracurium is 30 to 45 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics </strong>– <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">Atracurium</a> is metabolized through nonspecific plasma esterase-mediated hydrolysis and a nonenzymatic, pH- and temperature-dependent degradation called Hofmann elimination. Laudanosine is the final product of Hofmann elimination, a compound that was found to be epileptogenic in animal studies when administered in large doses [<a href="#rid130">130</a>]. Epileptogenic side effects have not been demonstrated in humans, and this byproduct has no significance at clinically relevant doses [<a href="#rid131">131</a>]. Metabolism is essentially independent of hepatic and renal function, and atracurium has no active metabolites. The volume of distribution of atracurium is 0.15 L/kg.</p><p></p><p class="headingAnchor" id="H3242425126"><span class="h3">Cisatracurium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">Cisatracurium</a> is the <em>cis</em>-isomer of <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a> and is four times more potent than atracurium. In contrast with atracurium, it does not cause histamine release.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing/onset of action</strong> – The intubating dose of <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a> of 0.15 to 0.2 mg/kg, or 3 x ED<sub>95</sub>, provides adequate intubating conditions in four to seven minutes. The maintenance dose of cisatracurium is 0.01 mg/kg or an infusion at 1 to 3 mcg/kg/min, guided by neuromuscular monitoring. Following an intubating dose of cisatracurium, the clinical duration of action is 35 to 50 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> – <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">Cisatracurium</a> is also primarily metabolized through Hofmann elimination. Cisatracurium has no active metabolites, and its volume of distribution is 0.16 L/kg.</p><p></p><p class="headingAnchor" id="H3111531992"><span class="h3">Mivacurium</span><span class="headingEndMark"> — </span>Mivacurium is a short-acting nondepolarizing benzylisoquinolinium NMBA that was developed as a nondepolarizing alternative to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. Large doses are required for intubation because of this drug's low potency. Clinical utility has been limited by the histamine release associated with these high doses [<a href="#rid129">129</a>]. Mivacurium is no longer available in the United States or Canada but is available in many other countries. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing/onset of action </strong>– An intubating dose of mivacurium of 0.2 mg/kg, or 3 x ED<sub>95</sub>, provides adequate intubating conditions in three to four minutes. The maintenance dose of mivacurium is 0.1 mg/kg [<a href="#rid132">132</a>], or an infusion at 5 to 8 mcg/kg/min, guided by neuromuscular monitoring. Following an intubating dose of mivacurium, the clinical duration of action is 15 to 20 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics </strong>– Mivacurium is mostly metabolized by butyrylcholinesterase and should not be used in patients with butyrylcholinesterase deficiency, as such patients will have unpredictable and prolonged response. Mivacurium has a volume of distribution of 0.2 L/kg. It does not have active metabolites.</p><p></p><p class="bulletIndent1">Reversal (antagonism) of mivacurium with either <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> or <a class="drug drug_general" data-topicid="9403" href="/d/drug information/9403.html" rel="external">edrophonium</a> is faster than spontaneous recovery [<a href="#rid133">133</a>], although neostigmine reversal of profound mivacurium block may result in prolongation of the block [<a href="#rid134">134</a>].</p><p></p><p class="bulletIndent1">Neuromuscular block that occurs after mivacurium administration in patients with pseudocholinesterase deficiency is not completely reversed by <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> [<a href="#rid135">135</a>], and recovery from neuromuscular block in this setting should be confirmed by objective monitoring, with a train-of-four ratio (TOFR) &gt;0.9.</p><p></p><p class="headingAnchor" id="H4184684632"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use and selection of neuromuscular blocking agents (NMBAs)</strong> – NMBAs are administered during anesthesia to facilitate endotracheal intubation and/or to improve surgical conditions  (<a class="graphic graphic_table graphicRef114082" href="/d/graphic/114082.html" rel="external">table 6</a>). Selection of NMBA is based on patient factors and the clinical indication. (See <a class="local">'Selection of neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1">Patient factors can affect the response to NMBAs, including neuromuscular disease  (<a class="graphic graphic_table graphicRef114209" href="/d/graphic/114209.html" rel="external">table 1</a>), burns, extremes of age, hepatic and renal dysfunction, and physiologic disturbances. Other medications (eg, inhaled anesthetics) can also affect the response to NMBAs. (See <a class="local">'Factors that affect the response to neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Depth of block</strong> – Deep neuromuscular block (ie, 0 to 1 twitch, post tetanic count ≥1 with neuromuscular monitoring) is used for endotracheal intubation, and for some surgical indications. We aim for a moderate level of neuromuscular block (ie, 1 to 3 twitches) for most surgical procedures. (See <a class="local">'Clinical use of neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoiding residual block</strong> – Full recovery of neuromuscular function (ie, train-of-four [TOF] ratio of ≥0.9) must be achieved prior to extubation of the trachea. Residual neuromuscular block is associated with weakness of upper airway muscles, increased risk of aspiration, hypoxemia, awareness during emergence from anesthesia, and increased postoperative pulmonary complications.(See <a class="local">'Avoidance of residual neuromuscular blockade'</a> above.)</p><p></p><p class="bulletIndent1">A strategy for avoidance of residual neuromuscular blockade should include (see <a class="local">'Avoidance of residual neuromuscular blockade'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use intermediate or short acting NMBAs whenever possible</p><p class="bulletIndent2"><span class="glyph">•</span>Avoid deep neuromuscular block (ie, train-of-four count [TOFC] of zero) when clinically appropriate</p><p class="bulletIndent2"><span class="glyph">•</span>Use objective neuromuscular monitoring whenever possible to guide administration of NMBAs and assess recovery</p><p class="bulletIndent2"><span class="glyph">•</span>Administer reversal agents in appropriate doses, guided by the degree of recovery from neuromuscular block (see <a class="local">'Reversal of neuromuscular block'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Extubate the trachea only after a TOF ratio ≥0.9 is achieved, as indicated by objective monitoring</p><p class="bulletIndent2"><span class="glyph">•</span>If a quantitative monitor is not available, we suggest administering <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> only when TOFC = 4 (as assessed at the adductor pollicis muscle) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We allow at least 10 minutes after neostigmine administration before tracheal extubation. (See <a class="local">'Anticholinesterases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reversal of block</strong> – Reversal of neuromuscular blockade can occur by spontaneous recovery, or by administration of reversal agents (ie, <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> or <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a>). Sugammadex can only be used to reverse block after administration of aminosteroid NMBAs (eg, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> or <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>). For patients who have received rocuronium or vecuronium and who require reversal of block, we suggest using sugammadex rather than neostigmine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Sugammadex reverses block more quickly and reliably than neostigmine, can be used to reverse deeper levels of neuromuscular block, and may be associated with reduced incidence of postoperative pulmonary complications (PPCs). (See <a class="local">'Sugammadex versus neostigmine'</a> above.)</p><p></p><p class="bulletIndent1">Where cost is an issue, it is reasonable to routinely use <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> and restrict the use of <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> to patients who are at higher risk of complications of postoperative residual neuromuscular block (eg, patients &gt;80 years of age or who undergo thoracic surgery, and/or patients who need reversal from deep levels of neuromuscular blockade (TOFC ≤3).</p><p></p><p class="bulletIndent1">The doses of <a class="drug drug_general" data-topicid="9693" href="/d/drug information/9693.html" rel="external">neostigmine</a> and <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> should be based on the level of existing neuromuscular block at the time of administration  (<a class="graphic graphic_table graphicRef114082" href="/d/graphic/114082.html" rel="external">table 6</a>). (See <a class="local">'Reversal of neuromuscular block'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification of NMBAs</strong> – NMBAs are classified according to their interaction with nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction (NMJ). <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> produces skeletal muscle relaxation by binding directly with nAChRs to cause prolonged depolarization. Nondepolarizing NMBAs act as competitive antagonists for acetylcholine at nAChRs to prevent the initiation of an action potential  (<a class="graphic graphic_table graphicRef114271" href="/d/graphic/114271.html" rel="external">table 5</a>). (See <a class="local">'Classification of neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a><strong> (depolarizer)</strong> – Succinylcholine is most often used for endotracheal intubation. It causes muscle fasciculations, an increase in serum potassium, and may cause postoperative myalgias. Succinylcholine is contraindicated in patients with severe burns, denervating neuromuscular diseases and stroke, susceptibility to malignant hyperthermia, and butyrylcholinesterase deficiency. (See <a class="local">'Succinylcholine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nondepolarizers</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">Rocuronium</a> and <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> are the commonly used intermediate duration aminosteroid nondepolarizing NMBAs. They are used for endotracheal intubation and to facilitate surgery. Vecuronium and rocuronium have minimal cardiovascular side effects. They should be avoided or used with careful monitoring in patients with renal or hepatic dysfunction  (<a class="graphic graphic_table graphicRef114207" href="/d/graphic/114207.html" rel="external">table 4</a>). (See <a class="local">'Steroidal neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">Cisatracurium</a>, <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a>, and mivacurium are benzylisoquinolinium nondepolarizing NMBAs. Cisatracurium and atracurium are intermediate duration of action NMBAs that are used for endotracheal intubation and for facilitation of surgery. They are metabolized through Hofmann elimination, and do not depend on renal or hepatic function. Atracurium, but not cisatracurium, releases histamine at higher doses and can cause hypotension  (<a class="graphic graphic_table graphicRef114210" href="/d/graphic/114210.html" rel="external">table 3</a>). (See <a class="local">'Atracurium'</a> above and <a class="local">'Cisatracurium'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mivacurium is a short acting NMBA that is metabolized by plasma butyrylcholinesterase, and should be avoided in patients with atypical or deficient butyrylcholinesterase. At high doses, mivacurium releases histamine  (<a class="graphic graphic_table graphicRef114271" href="/d/graphic/114271.html" rel="external">table 5</a>). (See <a class="local">'Mivacurium'</a> above.)</p><p></p><p class="headingAnchor" id="H1115491859"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Sorin Brull, MD, FCARCSI (Hon), who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Mohamed Naguib, MD, now deceased, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">CULLEN SC. Curare; its rational use as an adjunct to anesthesia. Surgery 1946; 20:200.</a></li><li><a class="nounderline abstract_t">Williams MT, Rice I, Ewen SP, Elliott SM. A comparison of the effect of two anaesthetic techniques on surgical conditions during gynaecological laparoscopy. Anaesthesia 2003; 58:574.</a></li><li><a class="nounderline abstract_t">King M, Sujirattanawimol N, Danielson DR, et al. Requirements for muscle relaxants during radical retropubic prostatectomy. Anesthesiology 2000; 93:1392.</a></li><li><a class="nounderline abstract_t">Lieutaud T, Billard V, Khalaf H, Debaene B. Muscle relaxation and increasing doses of propofol improve intubating conditions. Can J Anaesth 2003; 50:121.</a></li><li><a class="nounderline abstract_t">Mencke T, Echternach M, Kleinschmidt S, et al. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology 2003; 98:1049.</a></li><li><a class="nounderline abstract_t">Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102:438.</a></li><li><a class="nounderline abstract_t">Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99:1090.</a></li><li><a class="nounderline abstract_t">Weinstein JA, Matteo RS, Ornstein E, et al. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. Anesth Analg 1988; 67:1149.</a></li><li><a class="nounderline abstract_t">Lemmens HJ, Brodsky JB. Anesthetic drugs and bariatric surgery. Expert Rev Neurother 2006; 6:1107.</a></li><li><a class="nounderline abstract_t">Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesth Analg 2000; 91:237.</a></li><li><a class="nounderline abstract_t">Caldwell JE, Heier T, Wright PM, et al. Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 2000; 92:84.</a></li><li><a class="nounderline abstract_t">Leslie K, Sessler DI, Bjorksten AR, Moayeri A. Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium. Anesth Analg 1995; 80:1007.</a></li><li><a class="nounderline abstract_t">Heier T, Caldwell JE, Sessler DI, Miller RD. Mild intraoperative hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans. Anesthesiology 1991; 74:815.</a></li><li><a class="nounderline abstract_t">Weber V, Abbott TEF, Ackland GL. Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. Br J Anaesth 2021; 126:608.</a></li><li><a class="nounderline abstract_t">Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002; 96:202.</a></li><li><a class="nounderline abstract_t">KATZ B, MILEDI R. THE EFFECT OF CALCIUM ON ACETYLCHOLINE RELEASE FROM MOTOR NERVE TERMINALS. Proc R Soc Lond B Biol Sci 1965; 161:496.</a></li><li><a class="nounderline abstract_t">Waud BE, Waud DR. Interaction of calcium and potassium with neuromuscular blocking agents. Br J Anaesth 1980; 52:863.</a></li><li><a class="nounderline abstract_t">Hill GE, Wong KC, Shaw CL, Blatnick RA. Acute and chronic changes in intra- and extracellular potassium and responses to neuromuscular blocking agents. Anesth Analg 1978; 57:417.</a></li><li><a class="nounderline abstract_t">Yamauchi M, Takahashi H, Iwasaki H, Namiki A. Respiratory acidosis prolongs, while alkalosis shortens, the duration and recovery time of vecuronium in humans. J Clin Anesth 2002; 14:98.</a></li><li><a class="nounderline abstract_t">Szalados JE, Donati F, Bevan DR. Effect of d-tubocurarine pretreatment on succinylcholine twitch augmentation and neuromuscular blockade. Anesth Analg 1990; 71:55.</a></li><li><a class="nounderline abstract_t">Naguib M, Abdulatif M, Selim M, al-Ghamdi A. Dose-response studies of the interaction between mivacurium and suxamethonium. Br J Anaesth 1995; 74:26.</a></li><li><a class="nounderline abstract_t">Cooper R, Mirakhur RK, Clarke RS, Boules Z. Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium. Br J Anaesth 1992; 69:269.</a></li><li><a class="nounderline abstract_t">Soppitt AJ, Glass PS, el-Moalem H, et al. Duration and recovery profile of cisatracurium after succinylcholine during propofol or isoflurane anesthesia. J Clin Anesth 1999; 11:652.</a></li><li><a class="nounderline abstract_t">Naguib M, Samarkandi AH, Bakhamees HS, et al. Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids. Br J Anaesth 1995; 75:37.</a></li><li><a class="nounderline abstract_t">Naguib M, Samarkandi AH, Ammar A, et al. Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination. Anesthesiology 1998; 89:1116.</a></li><li><a class="nounderline abstract_t">Rupp SM, Miller RD, Gencarelli PJ. Vecuronium-induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans. Anesthesiology 1984; 60:102.</a></li><li><a class="nounderline abstract_t">Gencarelli PJ, Miller RD, Eger EI 2nd, Newfield P. Decreasing enflurane concentrations and d-tubocurarine neuromuscular blockade. Anesthesiology 1982; 56:192.</a></li><li><a class="nounderline abstract_t">Wulf H, Ledowski T, Linstedt U, et al. Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia. Can J Anaesth 1998; 45:526.</a></li><li><a class="nounderline abstract_t">Burkett L, Bikhazi GB, Thomas KC Jr, et al. Mutual potentiation of the neuromuscular effects of antibiotics and relaxants. Anesth Analg 1979; 58:107.</a></li><li><a class="nounderline abstract_t">Ornstein E, Matteo RS, Schwartz AE, et al. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 1987; 67:191.</a></li><li><a class="nounderline abstract_t">Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27:490.</a></li><li><a class="nounderline abstract_t">Martin BA, Kramer PM. Clinical significance of the interaction between lithium and a neuromuscular blocker. Am J Psychiatry 1982; 139:1326.</a></li><li><a class="nounderline abstract_t">Müller TC, Rocha JB, Morsch VM, et al. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. Biochim Biophys Acta 2002; 1587:92.</a></li><li><a class="nounderline abstract_t">Zencirci B. Sertraline-induced pseudocholinesterase enzyme deficiency. Int J Gen Med 2010; 3:375.</a></li><li><a class="nounderline abstract_t">Usubiaga JE, Standaert F. The effects of local anesthetics on motor nerve terminals. J Pharmacol Exp Ther 1968; 159:353.</a></li><li><a class="nounderline abstract_t">Matsuo S, Rao DB, Chaudry I, Foldes FF. Interaction of muscle relaxants and local anesthetics at the neuromuscular junction. Anesth Analg 1978; 57:580.</a></li><li><a class="nounderline abstract_t">Sahin SH, Colak A, Sezer A, et al. Effect of epidural levobupivacaine on recovery from vecuronium-induced neuromuscular block in patients undergoing lower abdominal surgery. Anaesth Intensive Care 2011; 39:607.</a></li><li><a class="nounderline abstract_t">Suzuki T, Mizutani H, Ishikawa K, et al. Epidurally administered mepivacaine delays recovery of train-of-four ratio from vecuronium-induced neuromuscular block. Br J Anaesth 2007; 99:721.</a></li><li><a class="nounderline abstract_t">Munakata K, Suzuki T, Watanabe N, et al. [Influence of epidural lidocaine injection on vecuronium-induced neuromuscular blockade]. Masui 2004; 53:1377.</a></li><li><a class="nounderline abstract_t">Vivancos GG, Klamt JG, Garcia LV. Effects of 2 mg.kg⁻¹ of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation. Rev Bras Anestesiol 2011; 61:1.</a></li><li><a class="nounderline abstract_t">Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. Rev Bras Anestesiol 2005; 55:371.</a></li><li><a class="nounderline abstract_t">Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. Acta Anaesthesiol Scand 2012; 56:474.</a></li><li><a class="nounderline abstract_t">Heggeri VM, Harbishettar AS, Deka A, Rajkhowa T. Intubating Conditions of two Different Doses of Rocuronium At 60 Seconds; by Clinical Assessment; and with T.O.F Response of Adductor Pollicis Muscle. J Clin Diagn Res 2015; 9:UC24.</a></li><li><a class="nounderline abstract_t">Kopman AF, Klewicka MM, Neuman GG. Reexamined: the recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset. Anesth Analg 2001; 93:954.</a></li><li><a class="nounderline abstract_t">Combes X, Andriamifidy L, Dufresne E, et al. Comparison of two induction regimens using or not using muscle relaxant: impact on postoperative upper airway discomfort. Br J Anaesth 2007; 99:276.</a></li><li><a class="nounderline abstract_t">Lundstrom L, Duez C, Norskov, et al. Effects of avoidance or use of neuromuscular blocking agents on outcomes iin tracheal intubation: a Cochrane systematic review. British Journal of Anaesthesia 2018; 120:1381.</a></li><li><a class="nounderline abstract_t">Hemmerling TM, Schmidt J, Hanusa C, et al. Simultaneous determination of neuromuscular block at the larynx, diaphragm, adductor pollicis, orbicularis oculi and corrugator supercilii muscles. Br J Anaesth 2000; 85:856.</a></li><li><a class="nounderline abstract_t">Mehta MP, Choi WW, Gergis SD, et al. Facilitation of rapid endotracheal intubations with divided doses of nondepolarizing neuromuscular blocking drugs. Anesthesiology 1985; 62:392.</a></li><li><a class="nounderline abstract_t">Engbaek J, Howardy-Hansen P, Ording H, Viby-Mogensen J. Precurarization with vecuronium and pancuronium in awake, healthy volunteers: the influence on neuromuscular transmission and pulmonary function. Acta Anaesthesiol Scand 1985; 29:117.</a></li><li><a class="nounderline abstract_t">Gueret G, Rossignol B, Kiss G, et al. Is muscle relaxant necessary for cardiac surgery? Anesth Analg 2004; 99:1330.</a></li><li><a class="nounderline abstract_t">Li YL, Liu YL, Xu CM, et al. The effects of neuromuscular blockade on operating conditions during general anesthesia for spinal surgery. J Neurosurg Anesthesiol 2014; 26:45.</a></li><li><a class="nounderline abstract_t">Blobner M, Frick CG, Stäuble RB, et al. Neuromuscular blockade improves surgical conditions (NISCO). Surg Endosc 2015; 29:627.</a></li><li><a class="nounderline abstract_t">Matsuzaki S, Jardon K, Maleysson E, et al. Impact of intraperitoneal pressure of a CO2 pneumoperitoneum on the surgical peritoneal environment. Hum Reprod 2012; 27:1613.</a></li><li><a class="nounderline abstract_t">Casanova J, Piñeiro P, De La Gala F, et al. [Deep versus moderate neuromuscular block during one-lung ventilation in lung resection surgery]. Rev Bras Anestesiol 2017; 67:288.</a></li><li><a class="nounderline abstract_t">Koo BW, Oh AY, Na HS, et al. Effects of depth of neuromuscular block on surgical conditions during laparoscopic colorectal surgery: a randomised controlled trial. Anaesthesia 2018; 73:1090.</a></li><li><a class="nounderline abstract_t">Kopman AF, Naguib M. Laparoscopic surgery and muscle relaxants: is deep block helpful? Anesth Analg 2015; 120:51.</a></li><li><a class="nounderline abstract_t">Baete S, Vercruysse G, Vander Laenen M, et al. The Effect of Deep Versus Moderate Neuromuscular Block on Surgical Conditions and Postoperative Respiratory Function in Bariatric Laparoscopic Surgery: A Randomized, Double Blind Clinical Trial. Anesth Analg 2017; 124:1469.</a></li><li><a class="nounderline abstract_t">Barrio J, Errando CL, García-Ramón J, et al. Influence of depth of neuromuscular blockade on surgical conditions during low-pressure pneumoperitoneum laparoscopic cholecystectomy: A randomized blinded study. J Clin Anesth 2017; 42:26.</a></li><li><a class="nounderline abstract_t">Fuchs-Buder T, Schmartz D, Baumann C, et al. Deep neuromuscular blockade improves surgical conditions during gastric bypass surgery for morbid obesity: A randomised controlled trial. Eur J Anaesthesiol 2019; 36:486.</a></li><li><a class="nounderline abstract_t">Cammu G, Boussemaere V, Foubert L, et al. Large bolus dose vs. continuous infusion of cisatracurium during hypothermic cardiopulmonary bypass surgery. Eur J Anaesthesiol 2005; 22:25.</a></li><li><a class="nounderline abstract_t">Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41:1095.</a></li><li><a class="nounderline abstract_t">Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol 2006; 72:97.</a></li><li><a class="nounderline abstract_t">Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107:130.</a></li><li><a class="nounderline abstract_t">Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med 2019; 7:129.</a></li><li><a class="nounderline abstract_t">de Boer HD, Brull SJ, Naguib M, et al. Neuromuscular monitoring and reversal: responses to the POPULAR study. Lancet Respir Med 2019; 7:e4.</a></li><li><a class="nounderline abstract_t">Thakkar KD, Hrishi AP. Neuromuscular monitoring and reversal: responses to the POPULAR study. Lancet Respir Med 2019; 7:e6.</a></li><li><a class="nounderline abstract_t">Plaud B, Gayat E, Nicolas P. Neuromuscular monitoring and reversal: responses to the POPULAR study. Lancet Respir Med 2019; 7:e5.</a></li><li><a class="nounderline abstract_t">Fuchs-Buder T. Neuromuscular monitoring and reversal: responses to the POPULAR study. Lancet Respir Med 2019; 7:e3.</a></li><li><a class="nounderline abstract_t">Blobner M, Hunter JM, Meistelman C, et al. Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR data. Br J Anaesth 2020; 124:63.</a></li><li><a class="nounderline abstract_t">Saager L, Maiese EM, Bash LD, et al. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. J Clin Anesth 2019; 55:33.</a></li><li><a class="nounderline abstract_t">Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg 2010; 111:120.</a></li><li><a class="nounderline abstract_t">Murphy GS, Szokol JW, Marymont JH, et al. Residual paralysis at the time of tracheal extubation. Anesth Analg 2005; 100:1840.</a></li><li><a class="nounderline abstract_t">Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007; 98:302.</a></li><li><a class="nounderline abstract_t">Carvalho H, Verdonck M, Cools W, et al. Forty years of neuromuscular monitoring and postoperative residual curarisation: a meta-analysis and evaluation of confidence in network meta-analysis. Br J Anaesth 2020; 125:466.</a></li><li><a class="nounderline abstract_t">Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology 2002; 96:45.</a></li><li><a class="nounderline abstract_t">Kopman AF, Zank LM, Ng J, Neuman GG. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg 2004; 98:102.</a></li><li><a class="nounderline abstract_t">Thilen SR, Weigel WA, Todd MM, et al. 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade. Anesthesiology 2023; 138:13.</a></li><li><a class="nounderline abstract_t">Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997; 87:1035.</a></li><li><a class="nounderline abstract_t">Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003; 98:1042.</a></li><li><a class="nounderline abstract_t">Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology 1982; 57:261.</a></li><li><a class="nounderline abstract_t">Bevan JC, Collins L, Fowler C, et al. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. Anesth Analg 1999; 89:333.</a></li><li><a class="nounderline abstract_t">Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg 2004; 99:1080.</a></li><li><a class="nounderline abstract_t">Tajaate N, Schreiber JU, Fuchs-Buder T, et al. Neostigmine-based reversal of intermediate acting neuromuscular blocking agents to prevent postoperative residual paralysis: A systematic review. Eur J Anaesthesiol 2018; 35:184.</a></li><li><a class="nounderline abstract_t">Fuchs-Buder T, Meistelman C, Alla F, et al. Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine. Anesthesiology 2010; 112:34.</a></li><li><a class="nounderline abstract_t">Caldwell JE. Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. Anesth Analg 1995; 80:1168.</a></li><li><a class="nounderline abstract_t">Naguib M, Kopman AF. Neostigmine-induced weakness: what are the facts? Anaesthesia 2018; 73:1055.</a></li><li><a class="nounderline abstract_t">Murphy GS, Szokol JW, Avram MJ, et al. Neostigmine Administration after Spontaneous Recovery to a Train-of-Four Ratio of 0.9 to 1.0: A Randomized Controlled Trial of the Effect on Neuromuscular and Clinical Recovery. Anesthesiology 2018; 128:27.</a></li><li><a class="nounderline abstract_t">Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care 2009; 24:29.</a></li><li><a class="nounderline abstract_t">Amorim P, Lagarto F, Gomes B, et al. Neostigmine vs. sugammadex: observational cohort study comparing the quality of recovery using the Postoperative Quality Recovery Scale. Acta Anaesthesiol Scand 2014; 58:1101.</a></li><li><a class="nounderline abstract_t">Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev 2017; 8:CD012763.</a></li><li><a class="nounderline abstract_t">Lee YJ, Oh AY, Koo BW, et al. Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: A randomised controlled trial. Eur J Anaesthesiol 2020; 37:196.</a></li><li><a class="nounderline abstract_t">White PF, Tufanogullari B, Sacan O, et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg 2009; 108:846.</a></li><li><a class="nounderline abstract_t">Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96:36.</a></li><li><a class="nounderline abstract_t">Sørensen MK, Bretlau C, Gätke MR, et al. Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial. Br J Anaesth 2012; 108:682.</a></li><li><a class="nounderline abstract_t">Bowdle TA, Haththotuwegama KJ, Jelacic S, et al. A Dose-finding Study of Sugammadex for Reversal of Rocuronium in Cardiac Surgery Patients and Postoperative Monitoring for Recurrent Paralysis. Anesthesiology 2023; 139:6.</a></li><li><a class="nounderline abstract_t">Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008; 100:373.</a></li><li><a class="nounderline abstract_t">Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103:695.</a></li><li><a class="nounderline abstract_t">Adams DR, Tollinche LE, Yeoh CB, et al. Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. Anaesthesia 2020; 75:348.</a></li><li><a class="nounderline abstract_t">Paredes S, Porter SB, Porter IE 2nd, Renew JR. Sugammadex use in patients with end-stage renal disease: a historical cohort study. Can J Anaesth 2020; 67:1789.</a></li><li><a class="nounderline abstract_t">Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig 2011; 31:101.</a></li><li><a class="nounderline abstract_t">Iwasaki H, Sasakawa T, Takahoko K, et al. A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal. J Anesth 2016; 30:534.</a></li><li><a class="nounderline abstract_t">de Kam PJ, Nolte H, Good S, et al. Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers. Br J Anaesth 2018; 121:758.</a></li><li><a class="nounderline abstract_t">Bhavani SS. Severe bradycardia and asystole after sugammadex. Br J Anaesth 2018; 121:95.</a></li><li><a class="nounderline abstract_t">Hunter JM, Naguib M. Sugammadex-induced bradycardia and asystole: how great is the risk? Br J Anaesth 2018; 121:8.</a></li><li class="breakAll">https://fis.fda.gov/sense/app/777e9f4d-0cf8-448e-8068-f564c31baa25/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis.</li><li class="breakAll">NDA 2225: Sugammadex Injection. Anesthetic and Analgesic Drug Products Advisory Committee (AC) Meeting November 6, 2015. Available from: https://www.fdanews.com/ext/resources/files/11-15/110615-merck.pdf?1515434323 (Accessed on July 05, 2018).</li><li><a class="nounderline abstract_t">Sanoja IA, Toth KS. Profound Bradycardia and Cardiac Arrest After Sugammadex Administration in a Previously Healthy Patient: A Case Report. A A Pract 2019; 12:22.</a></li><li><a class="nounderline abstract_t">Rahe-Meyer N, Fennema H, Schulman S, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology 2014; 121:969.</a></li><li><a class="nounderline abstract_t">Wu TS, Tseng WC, Lai HC, et al. Sugammadex and laryngospasm. J Clin Anesth 2019; 56:52.</a></li><li><a class="nounderline abstract_t">Greenaway S, Shah S, Dancey M. Sugammadex and laryngospasm. Anaesthesia 2017; 72:412.</a></li><li><a class="nounderline abstract_t">McGuire B, Dalton AJ. Sugammadex, airway obstruction, and drifting across the ethical divide: a personal account. Anaesthesia 2016; 71:487.</a></li><li><a class="nounderline abstract_t">Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2018; 73:631.</a></li><li><a class="nounderline abstract_t">Togioka BM, Yanez D, Aziz MF, et al. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. Br J Anaesth 2020; 124:553.</a></li><li><a class="nounderline abstract_t">Ledowski T, Szabó-Maák Z, Loh PS, et al. Reversal of residual neuromuscular block with neostigmine or sugammadex and postoperative pulmonary complications: a prospective, randomised, double-blind trial in high-risk older patients. Br J Anaesth 2021; 127:316.</a></li><li><a class="nounderline abstract_t">Kheterpal S, Vaughn MT, Dubovoy TZ, et al. Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. Anesthesiology 2020; 132:1371.</a></li><li><a class="nounderline abstract_t">Li G, Freundlich RE, Gupta RK, et al. Postoperative Pulmonary Complications' Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis. Anesthesiology 2021; 134:862.</a></li><li><a class="nounderline abstract_t">Ruetzler K, Li K, Chhabada S, et al. Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects. Anesth Analg 2022; 134:1043.</a></li><li><a class="nounderline abstract_t">Meadows JC. Fasciculation caused by suxamethonium and other cholinergic agents. Acta Neurol Scand 1971; 47:381.</a></li><li><a class="nounderline abstract_t">Schreiber JU, Lysakowski C, Fuchs-Buder T, Tramèr MR. Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. Anesthesiology 2005; 103:877.</a></li><li><a class="nounderline abstract_t">Naguib M, Lien CA, Aker J, Eliazo R. Posttetanic potentiation and fade in the response to tetanic and train-of-four stimulation during succinylcholine-induced block. Anesth Analg 2004; 98:1686.</a></li><li><a class="nounderline abstract_t">Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 1997; 52:244.</a></li><li><a class="nounderline abstract_t">Mintjens N, Brummans R, Soetens F, et al. Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium. Acta Anaesthesiol Scand 2021; 65:182.</a></li><li><a class="nounderline abstract_t">Raman SK, San WM. Fasciculations, myalgia and biochemical changes following succinylcholine with atracurium and lidocaine pretreatment. Can J Anaesth 1997; 44:498.</a></li><li><a class="nounderline abstract_t">Mace SE. Challenges and advances in intubation: rapid sequence intubation. Emerg Med Clin North Am 2008; 26:1043.</a></li><li><a class="nounderline abstract_t">Yasuda I, Hirano T, Amaha K, et al. Chronotropic effects of succinylcholine and succinylmonocholine on the sinoatrial node. Anesthesiology 1982; 57:289.</a></li><li><a class="nounderline abstract_t">Reddy JI, Cooke PJ, van Schalkwyk JM, et al. Anaphylaxis is more common with rocuronium and succinylcholine than with atracurium. Anesthesiology 2015; 122:39.</a></li><li><a class="nounderline abstract_t">Tran DT, Newton EK, Mount VA, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2015; :CD002788.</a></li><li><a class="nounderline abstract_t">Parmentier P, Dagnelie P. Dose-related tachycardia induced by pancuronium during balanced anaesthesia with and without droperidol. Br J Anaesth 1979; 51:157.</a></li><li><a class="nounderline abstract_t">Naguib M, Samarkandi AH, Bakhamees HS, et al. Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. Br J Anaesth 1995; 75:588.</a></li><li><a class="nounderline abstract_t">Chapple DJ, Miller AA, Ward JB, Wheatley PL. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth 1987; 59:218.</a></li><li><a class="nounderline abstract_t">Szakmany T, Woodhouse T. Use of cisatracurium in critical care: a review of the literature. Minerva Anestesiol 2015; 81:450.</a></li><li><a class="nounderline abstract_t">Dieck T, Steffens J, Sander B, et al. Propofol, remifentanil and mivacurium: fast track surgery with poor intubating conditions. Minerva Anestesiol 2011; 77:585.</a></li><li><a class="nounderline abstract_t">Maddineni VR, Mirakhur RK, McCoy EP. Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion. Anaesthesia 1994; 49:946.</a></li><li><a class="nounderline abstract_t">Kao YJ, Le ND. The reversal of profound mivacurium-induced neuromuscular blockade. Can J Anaesth 1996; 43:1128.</a></li><li><a class="nounderline abstract_t">Yang HS, Goudsouzian N, Martyn JA. Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro. Anesthesiology 1996; 84:936.</a></li></ol></div><div id="topicVersionRevision">Topic 94535 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20994801" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Curare; its rational use as an adjunct to anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12846625" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A comparison of the effect of two anaesthetic techniques on surgical conditions during gynaecological laparoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11149431" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Requirements for muscle relaxants during radical retropubic prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560300" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Muscle relaxation and increasing doses of propofol improve intubating conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717124" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428539" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The dose of succinylcholine in morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385356" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The effects of cisatracurium on morbidly obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904232" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pharmacodynamics of vecuronium and atracurium in the obese surgical patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16831123" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anesthetic drugs and bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10866919" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10638903" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7726398" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1673591" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mild intraoperative hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33218672" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753022" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14278410" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : THE EFFECT OF CALCIUM ON ACETYLCHOLINE RELEASE FROM MOTOR NERVE TERMINALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7437224" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interaction of calcium and potassium with neuromuscular blocking agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/568402" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute and chronic changes in intra- and extracellular potassium and responses to neuromuscular blocking agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943520" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Respiratory acidosis prolongs, while alkalosis shortens, the duration and recovery time of vecuronium in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2363529" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of d-tubocurarine pretreatment on succinylcholine twitch augmentation and neuromuscular blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7880700" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dose-response studies of the interaction between mivacurium and suxamethonium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1389845" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680107" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Duration and recovery profile of cisatracurium after succinylcholine during propofol or isoflurane anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7669466" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9821999" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6141748" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Vecuronium-induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7059028" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Decreasing enflurane concentrations and d-tubocurarine neuromuscular blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669005" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/571233" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mutual potentiation of the neuromuscular effects of antibiotics and relaxants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2886081" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3757936" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6812439" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical significance of the interaction between lithium and a neuromuscular blocker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12009429" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21189834" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sertraline-induced pseudocholinesterase enzyme deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5638657" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effects of local anesthetics on motor nerve terminals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/568429" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Interaction of muscle relaxants and local anesthetics at the neuromuscular junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21823377" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of epidural levobupivacaine on recovery from vecuronium-induced neuromuscular block in patients undergoing lower abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855735" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Epidurally administered mepivacaine delays recovery of train-of-four ratio from vecuronium-induced neuromuscular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15682798" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : [Influence of epidural lidocaine injection on vecuronium-induced neuromuscular blockade].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334502" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of 2 mg.kg⁻¹of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19468625" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of intravenous lidocaine on the pharmacodynamics of rocuronium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22260297" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26500985" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intubating Conditions of two Different Doses of Rocuronium At 60 Seconds; by Clinical Assessment; and with T.O.F Response of Adductor Pollicis Muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574363" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reexamined: the recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573390" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of two induction regimens using or not using muscle relaxant: impact on postoperative upper airway discomfort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of avoidance or use of neuromuscular blocking agents on outcomes iin tracheal intubation: a Cochrane systematic review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732519" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Simultaneous determination of neuromuscular block at the larynx, diaphragm, adductor pollicis, orbicularis oculi and corrugator supercilii muscles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3157332" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Facilitation of rapid endotracheal intubations with divided doses of nondepolarizing neuromuscular blocking drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2858145" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Precurarization with vecuronium and pancuronium in awake, healthy volunteers: the influence on neuromuscular transmission and pulmonary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502026" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Is muscle relaxant necessary for cardiac surgery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23887680" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The effects of neuromuscular blockade on operating conditions during general anesthesia for spinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25125097" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Neuromuscular blockade improves surgical conditions (NISCO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22454461" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of intraperitoneal pressure of a CO2 pneumoperitoneum on the surgical peritoneal environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28256331" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : [Deep versus moderate neuromuscular block during one-lung ventilation in lung resection surgery].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29727028" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effects of depth of neuromuscular block on surgical conditions during laparoscopic colorectal surgery: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25625254" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Laparoscopic surgery and muscle relaxants: is deep block helpful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28107276" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The Effect of Deep Versus Moderate Neuromuscular Block on Surgical Conditions and Postoperative Respiratory Function in Bariatric Laparoscopic Surgery: A Randomized, Double Blind Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803124" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Influence of depth of neuromuscular blockade on surgical conditions during low-pressure pneumoperitoneum laparoscopic cholecystectomy: A randomized blinded study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985536" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Deep neuromuscular blockade improves surgical conditions during gastric bypass surgery for morbid obesity: A randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816569" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Large bolus dose vs. continuous infusion of cisatracurium during hypothermic cardiopulmonary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366929" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16493386" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635478" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224322" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709453" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Neuromuscular monitoring and reversal: responses to the POPULAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709455" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Neuromuscular monitoring and reversal: responses to the POPULAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709454" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Neuromuscular monitoring and reversal: responses to the POPULAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709452" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Neuromuscular monitoring and reversal: responses to the POPULAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31607388" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30594097" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20442260" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920224" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Residual paralysis at the time of tracheal extubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307778" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32680607" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Forty years of neuromuscular monitoring and postoperative residual curarisation: a meta-analysis and evaluation of confidence in network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753000" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693596" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36520073" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366453" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717123" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7125261" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10439743" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385354" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189420" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Neostigmine-based reversal of intermediate acting neuromuscular blocking agents to prevent postoperative residual paralysis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952724" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7762847" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30132815" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Neostigmine-induced weakness: what are the facts?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28953501" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Neostigmine Administration after Spontaneous Recovery to a Train-of-Four Ratio of 0.9 to 1.0: A Randomized Controlled Trial of the Effect on Neuromuscular and Clinical Recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19272536" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Preclinical pharmacology of sugammadex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25179550" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Neostigmine vs. sugammadex: observational cohort study comparing the quality of recovery using the Postoperative Quality Recovery Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28806470" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31977627" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: A randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224792" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16357116" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315329" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37027807" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A Dose-finding Study of Sugammadex for Reversal of Rocuronium in Cardiac Surgery Patients and Postoperative Monitoring for Recurrent Paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18238834" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192761" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31721151" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949009" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Sugammadex use in patients with end-stage renal disease: a historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067251" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951159" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30236238" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29935601" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Severe bradycardia and asystole after sugammadex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29935599" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Sugammadex-induced bradycardia and asystole: how great is the risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29935599" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Sugammadex-induced bradycardia and asystole: how great is the risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29935599" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Sugammadex-induced bradycardia and asystole: how great is the risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30004912" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Profound Bradycardia and Cardiac Arrest After Sugammadex Administration in a Previously Healthy Patient: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25208233" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30690311" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Sugammadex and laryngospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28176323" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Sugammadex and laryngospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26871454" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Sugammadex, airway obstruction, and drifting across the ethical divide: a personal account.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29280475" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139135" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34127252" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Reversal of residual neuromuscular block with neostigmine or sugammadex and postoperative pulmonary complications: a prospective, randomised, double-blind trial in high-risk older patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282427" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730169" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Postoperative Pulmonary Complications' Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35020636" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5096762" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Fasciculation caused by suxamethonium and other cholinergic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192781" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15155329" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Posttetanic potentiation and fade in the response to tetanic and train-of-four stimulation during succinylcholine-induced block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124666" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cholinesterase. Its significance in anaesthetic practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010031" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9161744" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Fasciculations, myalgia and biochemical changes following succinylcholine with atracurium and lidocaine pretreatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059100" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Challenges and advances in intubation: rapid sequence intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7125266" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Chronotropic effects of succinylcholine and succinylmonocholine on the sinoatrial node.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25405395" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Anaphylaxis is more common with rocuronium and succinylcholine than with atracurium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26512948" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Rocuronium versus succinylcholine for rapid sequence induction intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/426993" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Dose-related tachycardia induced by pancuronium during balanced anaesthesia with and without droperidol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7577286" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3828170" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24721895" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Use of cisatracurium in critical care: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617621" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Propofol, remifentanil and mivacurium: fast track surgery with poor intubating conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7802237" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922768" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : The reversal of profound mivacurium-induced neuromuscular blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8638849" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
